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Abstract: Substituted disc-shaped perfluoroalkylated hexa-peri-
hexabenzocoronenes (HBC), known to self-assemble into conduct-
ing ordered architectures, were synthesized and characterized. A
systematic variation of the linear or branched perfluoroalkylated
side chains was performed in order to screen the influence of the lat-
eral chain on their one-dimensional self-aggregation. 
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Self-assembling is emerging as a widely used strategy in
supramolecular chemical synthesis, with the potential of
generating nonbiological structures with dimensions of up
to several hundred nanometers.1 As example of involved
intermolecular forces one could mention p-p interac-
tions,2 hydrogen bonding,3 donor–acceptor interactions,4
and reversible ligand–metal interactions.5 Molecules that
are promising self-assembling candidates with application
in advanced functional materials include liquid crystal
constituents,6 block polymers,7 hydrogen-bonded com-
plexes,8 and coordination polymers.9
Among supramolecular self-organizing systems, liquid
crystals, formed of disc-shaped molecules, are of particu-
lar interest.9a,10 They have great potential for incorporat-
ing desirable chemical functionalities in their periphery
and the physical properties of the supramolecular struc-
tures they form may, therefore, be tuned at nanoscaled di-
mensions. An outstanding class of polycondensed
aromatic hydrocarbons (PAH) are hexa-peri-hexabenzo-
coronene derivatives (HBC), which excel over their coun-
terparts due to their high chemical and thermal stability
and by their high charge carrier mobility measured in
bulk.11
The replacement of purely alkyl chains by partially per-
fluoroalkylated chains should, in principle, not alter the
electronic properties of these molecules, but should even-
tually prevent or reduce lateral aggregation of formed
one-dimensional self-aggregated molecular wires. Prom-
ising results in this respect involving some perfluoroalkyl-
ated HBC derivatives have recently been reported.12 In
order to investigate the influence of the nature of the lat-
eral chain, several derivatives have been systematically
synthesized and characterized. The lateral substituents, ei-
ther linear or branched, differ by the length of perfluoro-
alkyl chain and/or length of partitioning by the CH2
spacer. The derivatives reported herein are shown in
Figure 1. 
Figure 1 Hexa-peri-hexabenzocoronene target molecules
described in this paper
The most convenient way of synthesizing HBC deriva-
tives consists of cyclodehydrogenation of the correspond-
ing hexaphenylbenzene (HPB) under Kovacic
conditions.13 Among numerous variations of the Kovacic
conditions, the mild iron(III) chloride reagent, which acts
both as Lewis acid and as the oxidant, is superior to other
alternative reagents, as, in most cases, the reaction goes to
completion without unwanted chlorination. As the elec-
tron-withdrawing effect of a perfluorinated lateral chain
prevents the final cyclodehydrogenation reaction, a mini-
mum spacer of two CH2 groups is required between the ar-
omatic core and the perfluorinated part.14
Symmetrical HPB derivatives are best prepared by cyclo-
trimerization of an alkyne species.15 Although other tran-
sition metals, such as nickel and iron, or even silicon
catalyze the cyclotrimerization of alkynes to arenes, co-
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1
balt complexes such as Co2(CO)8 and CpCo(CO)2 are
among the most efficient.16
Cyclodehydrogenation, as well as cyclotrimerization, has
been studied extensively in the past for the preparation of
hexaalkyl-substituted HBC derivatives,17 but, neverthe-
less, needed modification for the preparation of perfluori-
nated analogues. 
The main challenge in preparing symmetrical perfluori-
nated HBC derivatives remains, therefore, in the prepara-
tion of correctly substituted tolane derivatives. These
starting substituted tolanes, used in turn for cyclotrimer-
ization, were found to be favorably made by tandem
Sonogashira cross-couping18 using the corresponding ha-
logenated aryl species bearing the desired perfluorinated
lateral chain. Mostly their preparation was very similar for
derivatives with the same length CH2 spacer, but varied
greatly when the number of CH2 groups changed.
The preparation of compounds 5a,b and 6a bearing a three
CH2 spacer between the phenyl ring and the perfluorinat-
ed tail has been reported involving a Wittig reaction of 4-
bromobenzaldehyde and [Ph3PCH2CH2Rfn]+I– (n = 6, 8,
10) and subsequent hydrogenation.19 Nevertheless, we de-
cided (Scheme 1) to use a different strategy due to easier
access to the Heck starting compounds. The perfluorinat-
ed allyl derivatives 3a,b, synthesized in two steps20 are
reacted with 4-bromo- or 4-iodobenzenediazonium tet-
rafluoroborate affording the desired cross-coupled prod-
ucts 4a–c by palladium-catalyzed Heck reaction;21
exclusively E-isomers were formed, as shown by 1H
NMR. The yield obtained from the iodinated diazonium
salt is much lower than that from using the bromine ana-
logue, because the iodinated diazonium salt undergoes
partially a twofold Heck reaction forming a dialkylated
product (up to 30%) which has to be separated by tedious
column chromatography purification.
Hydrogenation without halogen hydrogenolysis is best
done by using the mild rhodium/carbon catalyst in pen-
tane–dichloromethane (1:1). The reaction requires high
hydrogen pressure (up to 60 bars) and a reaction time of
around 12 hours to afford the hydrogenated compounds
5a and 6a quantitatively. Halogen exchange22 on 6a
with potassium iodide using nickel as catalyst yields the
more reactive iodinated compound 5b for subsequent
Sonogashira cross-coupling. 
HBC derivatives bearing a four-CH2 spacer were prepared
by a slightly different method, in which the alkyl–aryl
bond was formed prior to the attachment of the perfluori-
nated part to avoid any cross-coupling of perfluoroalkyl
substituents. Heck reaction of an analogue of compound 3
bearing four nonfluorinated carbons was found inappro-
priate as many side products were formed. 
As illustrated in Scheme 2, compound 7, formed by
Wurtz-type coupling,23 was reacted with the correspond-
ing perfluoroalkyl iodide (RfmI) in the presence of a cata-
lytic amount of 2,2¢-azobis(isobutyronitrile) to initiate the
reaction and 30% aqueous sodium metabisulfite solution
to reduce the formation of side products.20a Removal of
the iodine group of the side chain in 8a,b was achieved
with lithium aluminum hydride20c affording the desired
aryl bromides 9a,b without cleavage of the aryl bromide.
Even milder cleavage may be achieved using lauroyl per-
oxide in the presence of cyclohexane,24 a procedure which
afforded comparable yields in our case. Radical-mediated
halogen exchange furnished, finally, the iodoaryl deriva-
tives 5c,d.
Scheme 2 Three-step synthesis of the iodoaryl derivatives 5c,d
The preparation of the key aryl derivatives 5h,i is shown
in Scheme 3 with yield data in Table 1. All polyfluoro-
alkyl bromides 10a–e were obtained as colorless oils in
very good yield according to a published procedure.20c
The two-carbon elongation of the brominated alkynes was
achieved by their treatment with lithium acetylide–ethyl-
enediamine complex in dimethyl sulfoxide.25 In order to
improve the homogeneity of the reaction mixture, the
starting bromides were diluted with pentane prior to the
addition yielding the perfluoroalkynes 11a–e as colorless,
very volatile liquids in modest yield. The yields of the de-
rivatives bearing an eight CH2 spacer were, interestingly,
much better than those of the corresponding shorter ones,
probably due to lower volatility. An alternative way to
produce semiperfluorinated alkynes has been reported for
11c. Dimethylpropargyl alcohol was reacted with 6-bro-
mohex-1-ene, which was subsequently transformed by
addition of perfluorobutyl iodide. Reduction of the iodo
group followed by deprotection of the alkyne yielded
11c.26
The subsequent unfavorable Sonogashira cross-coupling
(the alkyne bears an alkyl and not an aryl substituent) of
11a–e was found to work best with Pd(PPh3)4 as the cata-
Scheme 1 Preparation of perfluoroalkylated iodoaryl derivatives
bearing a three-CH2 spacer
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lyst with 1-bromo-4-iodobenzene. Even at elevated reac-
tion temperatures (80 °C) no trace of any doubly alkylated
product was found. The cross-coupling was repeated sev-
eral times under various conditions in order to improve
the yield, but the simplest conditions [Pd(PPh3)4, CuI,
Et3N] excel over more elaborated ones [such as Pd(PPh3)4,
LDA, ZnBr2] that involve in situ preformed zinc deriva-
tives as active transmetalation species. Subsequent hydro-
genation of the alkynes 12a–e under 50 bar of hydrogen,
afforded the reduced perfluorinated bromoaryl key prod-
ucts 5e–g and 13a,b in quantitative yield as colorless oils.
Halogen exchange was only performed for two deriva-
tives 13a,b affording 5h,i.
The tandem Sonogashira reaction (Scheme 4, Table 2)
uses the standard PdCl2(PPh3)2/CuI catalyst with trimeth-
ylsilylacetylene, tetrahydrofuran as solvent and 1,8-diaza-
bicyclo[5.4.0]undec-7-ene–water as base to deprotect the
formed TMS intermediate. This procedure allowed for to-
tal suppression of the homocoupled product. The only im-
purity found was the unreacted halogenated starting
compound. It is noteworthy that the tandem Sonogashira
reaction was also attempted with unsaturated compound
4a. This reaction, however, afforded exclusively a tolane
derivative, in which HF was eliminated from the side
chain. We also attempted direct formation of tolane 14b
by twofold Kumada cross-coupling reaction between 11-
bromo-1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8-heptadecafluoro-
undecane and 1-bromo-4-[(4-bromophenyl)ethynyl]ben-
zene, but this reaction gave, at best, the desired product in
19% yield. The Kumada cross-coupling reaction seems to
be severely hampered due to the electron-withdrawing ef-
fect of the perfluorinated part, despite the three CH2 spac-
er. In contrary, both tolanes 14a,b were formed in good
yield for a tandem reaction. For tolane 14c, low yield was
obtained since large quantities of unreacted starting mate-
rial were recovered after the reaction. The high yield of
14d was surprising, as extremely low solubility, due to the
ten perfluorinated carbon tail, was expected to hamper the
reaction resulting in a drop in the yield instead of an in-
crease. In the case of the brominated precursors 5e,f, the
corresponding tolane 14e was afforded in very low yield,
only requiring separation from large amounts of recov-
ered starting material, whereas 14f was isolated in accept-
able yield. Tandem Sonogashira reaction using
brominated 5g or iodinated 5h,i yielded the tolanes 14g–i
in moderate to good yields. It appears that the influence of
the more reactive iodo group as compared to bromine is
negligible in the presence of bulky perfluoroalkylated
chains. 
Subsequent cobalt-mediated cyclotrimerization afforded
most of the desired HPB derivatives 15a–i in good yields.
The very low solubility of the tolanes 14b and 14d as well
as the corresponding HPB derivatives 15b and 15d pre-
vented completion of the reaction on one hand, and se-
verely hampered the purification of the obtained products
on the other. To overcome these difficulties hexafluo-
robenzene (HFB) was added as co-solvent to prevent in-
complete reaction due to co-precipitation of starting
material with the even less soluble product. Purification
was performed by filtration through a short silica gel plug
using hot benzotrifluoride (a,a,a-trifluorotoluene, BTF)
as solvent. It must be noted that HPB derivatives 15g and
15h bearing an eight CH2 spacer terminated by a short
perfluorinated part of four or six carbon atoms are the first
HPBs with linear, partially fluorinated side chains that are
oily instead of solid. This behavior was, to date, only re-
ported for HPB derivatives bearing purely alkyl chains or
branched lateral groups in their periphery.15b HPB 15i,
carrying eight perfluorinated carbon atoms, was again ob-
tained as a powder.
Scheme 3 Preparation of the brominated bromoaryls 5e–g and the iodoaryls 5h,i
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Table 1 Yields of All Derivatives Shown in Scheme 3
Rfn,m Starting compound Derivative Yield Derivative Yield Derivative Yield Derivative Yield 
n m (%) (%) (%) (%)
5 6 10a 11a 38 12a 38 5e 95
6 8 10b 11b 39 12b 36 5f 99
8 4 10c 11c 62 12c 78 5g 97
8 6 10d 11d 73 12d 35 13a 89 5h 88
8 8 10e 11e 44 12e 35 13b 93 5i 90
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Cyclodehydrogenation of all HPB derivatives bearing lin-
ear perfluoralkylated chains 15a–i afforded the corre-
sponding HBC derivatives in moderate yields. HPB
carrying short perfluorinated parts or long alkyl parts, nor-
mally well soluble in dichloromethane, were reacted using
the standard iron(III) chloride/nitromethane protocol27
whereas hexafluorobenzene was added as co-solvent for
less soluble HPB derivatives as otherwise the transforma-
tion could not be completed. After the reaction the crude
mixtures were quenched by the addition of methanol,
which induced precipitation of the desired HBC deriva-
tives, commonly as brown solids. Precipitation from com-
mon organic solvents (Et2O, CH2Cl2, MeNO2, and EtOH)
and a fluorinated solvent such as benzotrifluoride or
hexafluorobenzene yielded, after several suction filtra-
tions over Millipore®, the desired HBCs as yellow solids.
Interestingly, the four CH2 spacer, independent on the
length of the perfluoro part [4 CF2 (1c), 6 CF2,27 8 CF2,14
10 CF2 (1d)], proved to be ideal for purification as precip-
itation from benzotrifluoride and hexafluorobenzene af-
forded these products as very bright yellow solids.27
Despite of the fact that HBCs 1g and 1h, bearing short
perfluorinated parts, were even moderately soluble in
common organic solvents, their purification proved to be
more cumbersome. Due to moderate solubility of the later,
silica gel filtration using hot benzotrifluoride, hot toluene,
diethyl ether, or dichloromethane was attempted, but the
HBC stuck irreversibly to the silica gel. Chromatography
on preparative TLC plates afforded an observable migra-
tion, but it was impossible to recover the compound from
the solid support. The usual solublilization/precipitation
technique was therefore applied yielding HBC 1h as a
dark yellow solid whereas HBC 1g remained a dark pow-
der. MALDI-TOF analysis of 1g revealed a mixture of
chlorinated products (up to five chlorine substituents) of
the target HBC. We assume that chlorination was pro-
voked by the high solubility of the final product, since this
chlorination occurred even at room temperature.
HBC 1i with its eight perfluorinated carbons showed rath-
er low solubility. Purification was, therefore, attempted by
suspending 1i in common organic solvents followed by
suction filtration over Millipore®. Unfortunately the
black impurity could not be removed in this way. Only re-
peated precipitation from refluxing 1,2,4-trichloroben-
zene (TCB) afforded 1i as dark yellow solid. 
An alternative very short sequence to prepare symmetri-
cally substituted tolane derivatives consists of a twofold
Kumada cross-coupling reaction of a perfluorinated bro-
moalkane with 1-bromo-4-[(4-bromophenyl)ethynyl]ben-
Scheme 4 Formation of HBC derivatives bearing linear perfluorinated side chains
Rf
n,m
X
H TMS
Rf
n,m
Rf
n,m
Rf
n,m
Rf
n,m
Rf
n,m
Rf
n,m
Rf
n,m
Rf
n,m
Rf
n,m
Rf
n,m
Rf
n,m
Rf
n,m
Rf
n,m
Rf
n,m
PdCl
2
(PPh
3
)
2
, CuI
THF, DBU, H
2
O
Co
2
(CO)
8
dioxane
FeCl
3
, MeNO
2
CH
2
Cl
2
, HFB
5a–i
14a–i
15a–i
1a–i
Table 2 Yields of All Derivatives Presented in Scheme 4
Rfn,m X Starting compound Derivative Yield Derivative Yield Derivative Yield 
n m (%) (%) (%)
3 6 I 5a 14a 61 15a 86 1a 33
3 8 I 5b 14b 66 15b 84 1b 56
4 4 I 5c 14c 20 15c 95 1c 55
4 10 I 5d 14d 80 15d 85 1d 70
5 6 Br 5e 14e 6 15e 79 1e 60
6 8 Br 5f 14f 46 15f 64 1f 65
8 4 Br 5g 14g 50 15g 73 1g 46
8 6 I 5h 14h 21 15h 92 1h 64
8 8 I 5i 14i 21 15i 51 1i 40
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zene (16) (Scheme 5). Unfortunately the yield proved to
be at best moderate and, in addition, not reproducible, the
reason being, most probably, incomplete Grignard forma-
tion of the perfluorinated bromoalkyl hindered by micelle
formation.28 The very long reaction time (one week) of the
subsequent Kumada cross-coupling, underlined these dif-
ficulties. Out of the large variety of different catalysts test-
ed PdCl2(dppf)·CH2Cl229 proved to be the most promising,
since with other catalysts, such as Pd2(dba)3 or
Pd(OAc)230 the reaction did not go to completion. 
Only the use of highly pure tolane 14j allowed the prepa-
ration of the desired HPB derivative 15j in good yield as
a white powder, as the remaining impurities of the Kumada
cross-coupling catalyst appeared to poison the cobalt cat-
alyst, preventing, therefore, the cyclotrimerization. 
Oxidation of HPB 15j was attempted first by using
iron(III) chloride in nitromethane and dichloromethane as
solvent. However, only starting material was recovered,
presumably because the solubility was too low for the re-
action to occur. Only by adding hexafluorobenzene as a
co-solvent was the desired HBC 1j obtained as slightly
brown-yellow powder after several re-precipitations from
benzotrifluoride and hexafluorobenzene solutions.
To further increasing the fluorine coat of the HBC colum-
nar stacks, HBC derivatives carrying branched perfluori-
nated side chains were designed. One derivative 2a was
decorated with six branched chains each carrying two per-
fluorobutyl end groups. Modeling of the geometry of this
side chain revealed a T-shaped arrangement of the per-
fluorinated end part with respect to the CH2 spacer at the
branching point. This geometry inherently imposes large
steric hindrance on the p–p stacking. To reduce this steric
hindrance two other derivatives were added, one with a
longer CH2 spacer after the branching point 2b and a sec-
ond derivative with an elongated CH2 spacer before and
after the branching point 2c.
The addition of a second perfluorinated tail onto a per-
fluoroalkylated allyl derivative 20 proved to work
smoothly, but required, in general, longer reaction times.
Furthermore the addition of several portions of the radical
initiator (AIBN) were needed to afford the desired
branched iodide 19a after distillation (Scheme 6). The an-
alogue 19b with a five-carbon spacer between the perflu-
orinated end tails was synthesized by twofold Grignard
reaction on ethyl formate (17)31 followed by iodination of
the obtained alcohol 18. Interestingly, all iodination at-
tempts using hydrogen iodide and aliquat 336 as phase-
transfer catalyst failed completely, most probably due to
solubility problems. Only the use of tetrabutylammonium
iodide in the presence of 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone and triphenylphosphine afforded the de-
sired iodide 19b.32
The subsequent Kumada reaction was found to be very
tricky as the reaction was very sensitive to the applied
conditions. It appeared crucial that the allylmagnesium
bromide is added slowly over several hours at 0 °C as
otherwise many side products are formed. Again
PdCl2(dppf)·CH2Cl2 was found to be the most adapted cat-
alyst to form selectively 21a,b.
Heck reaction of the branched perfluorinated precursors
21a,b with reactive 4-bromobenzenediazonium tetrafluo-
roborate did not work properly. Different catalytic sys-
tems were tested, from which Pd(OAc)2/CaCO3 and
Pd2(dba)3/NaOAc excelled over all the others. Subsequent
hydrogenation of 22a,b afforded the desired aryl deriva-
tives carrying branched perfluoroalkylated side chains
23a,b.
Reaction of iodide 19b with 5-bromopent-1-ene under
Kumada cross-coupling conditions did not allow the di-
rect preparation of the 21b analogue. The Kumada cross-
coupling worked only by using very reactive allylmagne-
sium bromide. Hence 21b was oxidized33 to the alcohol 24
which was, thereafter, converted into its brominated ana-
logue 25 by using tetrabutylammonium bromide, 2,3-
dichloro-5,6-dicyano-1,4-benzoquinone, and triphenyl-
phosphine. Subsequent acylation using lithium acetylide–
ethylenediamine complex in a mixture of dimethyl sulfox-
ide and pentane afforded finally compound 26
(Scheme 7). Sonogashira cross-coupling of 26 gave the
desired aryl derivative 27 in low yield. The low reactivity
of the starting alkyne 26 was the reason that no traces of
doubly coupled product were found. Hydrogenation of 27
using the already discussed rhodium/carbon conditions
afforded the desired aryl bromide 23c in good yield.
Conversion of the brominated aryl derivatives 23a–c with
their branched chains into the corresponding tolanes was
Scheme 5 Tolane preparation via Kumada cross-coupling followed by HBC formation
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performed by tandem Sonogashira reactions. Purification
was achieved for all three derivatives by column chroma-
tography over silica gel. The branched T-shaped lateral
chain seems to impede considerably the p-p-aggregation
of the central part as 28a–c are the first reported tolanes
that are obtained as oils instead of solids. The highly sol-
uble tolanes afforded after Co2(CO)8-mediated cyclotri-
merization the desired HPB derivatives 29a–c in
moderate to high yields (Scheme 8). These oily com-
pounds had to be purified by column chromatography.
Scheme 6 Formation of branched polyfluoroalkyl-substituted aryl bromides 23a,b
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Scheme 7 Preparation of derivative 23c
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Scheme 8 Formation of HBC derivatives 2a–c bearing branched perfluoroalkylated side chains
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The oily consistence of HPB derivatives was already men-
tioned in literature for compounds that carry long linear
(>C12) or branched alkyl chains in their periphery.34
The oxidation of HPB 29a–c was performed under mild
iron(III) chloride conditions (Scheme 8). As a solvent
dichloromethane was largely sufficient, since all starting
materials were oils and, therefore, readily dissolved in
dichloromethane. The purification of HBC 2a was per-
formed in the usual way by precipitation of the HBC from
benzotrifluoride and hexafluorobenzene solution by the
addition of diethyl ether, pentane, and methanol, which
yielded finally the desired HBC 2a as a yellow powder,
whereas HBCs 2b,c were obtained as dark powders. 
All reagents and solvents were purchased from commercial sources
and used without further purification. THF and CH2Cl2 were dried
and deoxygenated by the Grubbs method.35 All reactions were per-
formed under inert atmosphere (N2 or Ar). 1H and 13C NMR spectra
were recorded on a Bruker DPX 360 or a Bruker DRX 500 spec-
trometer, using CDCl3 or HFB as solvent. Mass spectra were re-
corded on a Finnigan Thermo Quest GC/MS Voyager spectrometer,
a Bruker 4.7 T BioAPEX II FT-ICR spectrometer using DCTB
(trans-2-[3-(4-tert-butylphenyl)-2-methylprop-2-enylidene]malo-
nonitrile) as matrix, or a Bruker Ultraflex II spectrometer. Analyti-
cal TLC was performed on Merck Kieselgel 60 F254 pre-coated
glass plates and visualized by spraying with a KMnO4 soln. 
2,5,8,11,14,17-Hexakis(4,4,5,5,6,6,7,7,8,8,9,9,9-tridecafluoro-
nonyl)hexabenzo[bc,ef,hi,kl,no,qr]coronene (1a); Typical 
Procedure
In a 3-necked flask, HPB 15a (0.2 g, 74 mmol) was dissolved in an-
hyd CH2Cl2 (15 mL) under an inert atmosphere. At the same time a
soln of FeCl3 (433 mg, 2.67 mmol, 3 equiv/H to be removed) was
prepared in MeNO2 (5 mL). The FeCl3 soln was added to the soln
of 15a at 45 °C drop by drop with a syringe. Argon was bubbled
through the mixture by a Teflon capillary during the entire reaction.
After 6 h the mixture was quenched by the addition of MeOH (20
mL). The black precipitate was collected by suction filtration over
Millipore® and was suspended in various common organic solvents
(CH2Cl2, MeOH, Et2O, and pentane). The suspensions formed were
each treated in an ultrasonic bath for 30 min followed by reflux for
1 h. After 2 h of cooling in the refrigerator the suspensions were fil-
tered over Millipore® to yield 1a (62 mg, 33%) as a bright yellow
powder. 
1H NMR (500 MHz, HFB, CDCl3): d = 8.69 (br s, 12 H, Ar), 3.55
(br s, 12 H), 2.74 (m, 24 H).
MS (MALDI-ICR, DCTB): m/z (%) = 2682.22 (100) ([M+], calcd
for C96H48F78: 2682.25), 2336.20 (20).
UV/VIS (BTF, 10–5 M): l (e) = 344, 361 (5.6 × 103), 386, 412 nm.
2,5,8,11,14,17-Hexakis(4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,11-
heptadecafluoroundecyl)hexabenzo[bc,ef,hi,kl,no,qr]coronene 
(1b)
As described for 1a using HPB 15b (50 mg, 15 mmol), FeCl3 (220
mg, 1.36 mmol, 7.5 equiv/H to be removed), CH2Cl2 (5 mL),
MeNO2 (4 mL), and HFB (5 mL) gave 1b (28 mg, 56%).
1H NMR (500 MHz, HFB, CDCl3): d = 8.95 (s, 12 H, Ar), 3.61 (br
s, 12 H, CH2), 2.73 (br s, 24 H, CH2). 
MS (MALDI-ICR, DCTB): m/z (%) = 3282.21 (100) ([M+], calcd
for C108H48F102: 3282.21), 2836.20 (10).
UV/VIS (BTF, 10–6 M): l (e) = 352, 369 (1.5 × 105), 396 nm.
2,5,8,11,14,17-Hexakis(5,5,6,6,7,7,8,8,8-nonafluorooctyl)hexa-
benzo[bc,ef,hi,kl,no,qr]coronene (1c)
As described for 1a using HPB 15c (0.2 g, 92 mmol), FeCl3 (535 mg,
3.3 mmol, 3.0 equiv/H to be removed), CH2Cl2 (15 mL), and
MeNO2 (5 mL) gave 1c (110 mg, 55%).
1H NMR (500 MHz, HFB, CDCl3): d = 9.06 (s, 12 H, Ar), 3.57 (t,
J = 7.8 Hz, 12 H, CH2), 2.59–2.63 (m, 24 H, CH2), 2.30 (quint,
J = 7.8 Hz, 12 H, CH2).
MS (MALDI-ICR, DCTB): m/z (%) = 2166.36 (100) ([M+], calcd
for C90H60F54: 2166.38), 1906.34 (20), 1644.28 (10), 1384.27 (5).
UV/VIS (BTF, 10–6 M): l (e) = 343, 360 (1.2 × 105), 391 nm.
2,5,8,11,14,17-
Hexakis(5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,14-
henicosafluorotetradecyl)hexabenzo[bc,ef,hi,kl,no,qr]coronene 
(1d)
As described for 1a using HPB 15d (0.1 g, 25 mmol), FeCl3 (366
mg, 2.26 mmol, 7.5 equiv/H to be removed), CH2Cl2 (10 mL),
MeNO2 (8 mL), and HFB (10 mL) gave 1d (70 mg, 70%).
1H NMR (500 MHz, CDCl3): d = 9.12 (br s, 12 H, Ar), 3.58 (br s,
12 H, CH2), 2.52 (br s, 24 H, CH2), 2.37 (br s, 12 H, CH2).
MS (MALDI-ICR, DCTB): m/z (%) = 3966.22 (100) ([M+], calcd
for C126H60F126: 3966.27), 3405.01 (43).
UV/VIS (BTF, 10–5 M): l (e) = 364 nm (4.2 × 104).
2,5,8,11,14,17-Hexakis(6,6,7,7,8,8,9,9,10,10,11,11,11-trideca-
fluoroundecyl)hexabenzo[bc,ef,hi,kl,no,qr]coronene (1e)
As described for 1a using HPB 15e (0.1 g, 35 mmol), FeCl3 (340 mg,
2.1 mmol, 5.0 equiv/H to be removed), CH2Cl2 (20 mL), and
MeNO2 (8 mL) gave 1e (60 mg, 60%).
1H NMR (360 MHz, HFB, CDCl3): d = 8.99 (br s, 12 H, Ar), 3.55
(br s, 12 H, CH2), 2.50 (br s, 24 H, CH2), 2.15 (br s, 24 H).
MS (MALDI-ICR, DCTB): m/z (%) = 2850.44 (100) ([M+], calcd
for C108H72F78: 2850.44), 2476.40 (50), 2101.36 (15), 1725.33 (10).
UV/VIS (BTF, 10–6 M): l (e) = 346, 360 (2.8 × 105), 391 nm.
2,5,8,11,14,17-
Hexakis(7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,14-hepta-
decafluorotetradecyl)hexabenzo[bc,ef,hi,kl,no,qr]coronene (1f)
As described for 1a using HPB 15f (0.2 g, 56 mmol), FeCl3 (820 mg,
5.0 mmol, 7.5 equiv/H to be removed), CH2Cl2 (15 mL), MeNO2
(12 mL), and HFB (15 mL) gave 1f (130 mg, 65%).
1H NMR (360 MHz, HFB, CDCl3): d = 8.83 (br s, 12 H, Ar), 3.48
(br s, 12 H, CH2), 2.46 (br s, 24 H, CH2), 2.10 (br s, 36 H, CH2).
MS (MALDI-ICR, DCTB): m/z (%) = 3534.55 (100) ([M+], calcd
for C126H84F102: 3534.49), 3046.68 (24).
UV/VIS (BTF, 10–6 M): l (e) = 346, 360 (2.5 × 105), 391 nm.
2,5,8,11,14,17-Hexakis(9,9,10,10,11,11,12,12,12-nonafluoro-
dodecyl)hexabenzo[bc,ef,hi,kl,no,qr]coronene (1g)
As described for 1a using HPB 15g (1.0 g, 0.4 mmol), FeCl3 (5.8 g,
36 mmol, 7.5 equiv/H to be removed), CH2Cl2 (80 mL), and MeNO2
(20 mL) gave 1g (0.46 g, 46%).
MS (MALDI-ICR, DCTB): m/z (%) = 2502.1 (100) ([M+], calcd for
C114H108F54: 2502.76), 2536.1 (25) [M – H + Cl]+, 2570.0 (16) [M –
2 H + 2 Cl]+, 2604.0 (5) [M – 3 H + 3 Cl]+, 2637.9 (2) [M – 4 H +
4 Cl]+.
UV/VIS (BTF, 10–6 M): l (e) = 323, 372 (5.2 × 105), 451 nm.
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2,5,8,11,14,17-Hexakis(9,9,10,10,11,11,12,12,13,13,14,14,14-
tridecafluorotetradecyl)hexabenzo[bc,ef,hi,kl,no,qr]coronene 
(1h)
As described for 1a using HPB 15h (0.1 g, 32 mmol), FeCl3 (468
mg, 2.9 mmol, 7.5 equiv/H to be removed), CH2Cl2 (18 mL), and
MeNO2 (4 mL) gave 1h (64 mg, 64%).
MS (MALDI-TOF, DCTB): m/z (%) = 3103.4 (35) ([M+], calcd for
C126H108F78: 3102.72), 1001.6 (100). 
UV/VIS (BTF, 10–6 M): l (e) = 371 nm (9.2 × 105).
2,5,8,11,14,17-
Hexakis(9,9,10,10,11,11,12,12,13,13,14,14,15,15,16,16,16-hep-
tadecafluorohexadecyl)hexabenzo[bc,ef,hi,kl,no,qr]coronene 
(1i)
As described for 1a using HPB 15i (0.2 g, 54 mmol), FeCl3 (523 mg,
3.2 mmol, 5.0 equiv/H to be removed), CH2Cl2 (30 mL), MeNO2
(12 mL), and HFB (10 mL) gave 1i (80 mg, 40%).
1H NMR (360 MHz, HFB, CDCl3): d = 9.00 (br s, 12 H, Ar), 3.51
(br s, 12 H, CH2), 2.34 (br s, 24 H, CH2), 1.88 (br s, 60 H, CH2).
MS (MALDI-ICR, DCTB): m/z (%) = 3702.71 (100) ([M+], calcd
for C138H108F102: 3702.68), 3186.87 (17), 2656.42 (12), 2139.37 (8).
UV/VIS (BTF, 10–6 M): l (e) = 345, 360 (1.5 × 105), 391 nm.
2,5,8,11,14,17-
Hexakis(6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,13-heptadeca-
fluorotridecyl)hexabenzo[bc,ef,hi,kl,no,qr]coronene (1j)
As described for 1a using HPB 15j (0.1 g, 28 mmol), FeCl3 (423 mg,
2.6 mmol, 7.5 equiv/H to be removed), CH2Cl2 (10 mL), MeNO2 (8
mL), and HFB (10 mL) gave 1j (54 mg, 54%).
1H NMR (360 MHz, CDCl3): d = 9.06 (br s, 12 H, Ar), 3.60 (br s,
12 H, CH2), 2.65 (br s, 24 H, CH2), 2.20 (br s, 24 H, CH2).
MS (MALDI-ICR, DCTB): m/z (%) = 3450.50 (100) ([M+], calcd
for C120H78F102: 3450.40), 2976.34 (10).
UV/VIS (BTF, 10–6 M): l (e) = 345, 360 (1.9 × 105), 391 nm.
2,5,8,11,14,17-Hexakis[6,6,7,7,8,8,9,9,9-nonafluoro-4-
(2,2,3,3,4,4,5,5,5-nonafluoropentyl)nonyl]hexa-
benzo[bc,ef,hi,kl,no,qr]coronene (2a)
As described for 1a using HPB 29a (0.2 g, 55 mmol), FeCl3 (800 mg,
4.9 mmol, 7.5 equiv/H to be removed), CH2Cl2 (10 mL), MeNO2 (8
mL), and HFB (10 mL) gave 2a (170 mg, 84%).
1H NMR (360 MHz, CDCl3): d = 9.29 (br s, 12 H, Ar), 3.67 (br s,
12 H, CH2), 2.99 (br s, 6 H, CH), 2.44–2.71 (m, 36 H, CH2), 2.54
(m, 12 H, CH2).
MS (MALDI-ICR, DCTB): m/z (%) = 3642.43 (100) ([M+], calcd
for C126H78F108: 3642.44).
UV/VIS (BTF, 10–6 M): l (e) = 346, 361 (2.4 × 105), 391 nm.
2,5,8,11,14,17-Hexakis[7,7,8,8,9,9,10,10,11,11,12,12,12-tri-
decafluoro-4-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)do-
decyl]hexabenzo[bc,ef,hi,kl,no,qr]coronene (2b)
As described for 1a using HPB 29b (142 mg, 30 mmol), FeCl3 (413
mg, 2.54 mmol, 7.0 equiv/H to be removed), CH2Cl2 (15 mL), and
MeNO2 (6 mL) gave 2b (118 mg, 83%).
MS (MALDI-TOF, DCTB): m/z (%) = 5011.66 (100) ([M+], calcd
for C162H102F156: 5010.55).
UV/VIS (BTF, 10–6 M): l (e) = 345, 361 (3.5 × 105), 390 nm.
2,5,8,11,14,17-Hexakis[9,9,10,10,11,11,12,12,13,13,14,14,14-
tridecafluoro-6-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)tet-
radecyl]hexabenzo[bc,ef,hi,kl,no,qr]coronene (2c)
As described for 1a using HPB 29c (55 mg, 10 mmol), FeCl3 (153
mg, 0.94 mmol, 7.8 equiv/H to be removed), CH2Cl2 (15 mL), and
MeNO2 (1.5 mL) gave 2c (40 mg, 73%).
MS (MALDI-TOF, DCTB): m/z (%) = 5180.04 (100) ([M+], calcd
for C174H126F156: 5178.74).
UV/VIS (BTF, 10–6 M): l (e) = 345, 360 (1.3 × 105), 390 nm.
1-Iodo-4-(4,4,5,5,6,6,7,7,8,8,9,9,9-tridecafluoronon-1-enyl)ben-
zene (4a); Typical Procedure
4-Iodobenzenediazonium tetrafluoroborate (9.7 g, 30.5 mmol),
Pd2(dba)3 (508 mg, 0.56 mmol), and NaOAc (7.9 g, 97.0 mmol)
were added to a 2-necked round-bottomed flask equipped with a re-
flux condenser under an inert atmosphere. Degassed MeCN (100
mL) was added. Compound 3a (10 g, 27.8 mmol) was degassed in
a separate flask and was diluted with MeCN (40 mL) and syringed
into the reaction vessel. The inert gas entry was changed against a
bubble counter. The mixture was stirred at r.t. for 4 h until the for-
mation of N2 had stopped. All volatiles were removed under re-
duced pressure yielding a dark brown solid that was dissolved in
pentane (400 mL) and filtered through a plug of silica gel (pentane)
under reduced pressure. After removing all volatiles, 4a was recov-
ered as slightly yellow solid which was further purified by column
chromatography (pentane). Evaporating all volatiles from the de-
sired fractions yielded 4a (10.14 g, 59%) as a white solid; Rf = 0.66
(pentane).
1H NMR (360 MHz, CDCl3): d = 7.66 (d, J = 8.2 Hz, 2 H, Ar), 7.12
(d, J = 8.2 Hz, 2 H, Ar), 6.55 (d, J = 15.4 Hz, 1 H, CH), 6.15 (dt,
J = 15.4, 7.5 Hz, 1 H, CH), 3.00 (dt, J = 17.9, 7.5 Hz, 2 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 137.75, 136.22, 135.66, 128.17,
117.00 (t, J = 4.6 Hz), 105.70–120.02 (m, Rf6), 93.57, 35.14 (t,
J = 22.8 Hz).
MS (EI, 70 eV): m/z (%) = 562.8 (7) [M+], 116.0 (100).
1-Bromo-4-(4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,11-heptadeca-
fluoroundec-1-enyl)benzene (4b)
As described for 4a using 3b (13.0 g, 28.25 mmol), 4-bromoben-
zenediazonium tetrafluoroborate (8.4 g, 31.08 mmol), Pd2(dba)3
(440 mg, 0.42 mmol), NaOAc (8.1 g, 9.89 mmol), and MeCN (140
mL)  gave 4b (16.2 g, 93%); Rf = 0.54 (pentane).
1H NMR (360 MHz, CDCl3): d = 7.46 (d, J = 8.2 Hz, 2 H, Ar), 7.25
(d, J = 8.2 Hz, 2 H, Ar), 6.56 (d, J = 15.4 Hz, 1 H, CH), 6.13 (dt,
J = 15.4, 7.5 Hz, 1 H, CH), 3.00 (dt, J = 17.7, 7.5 Hz, 2 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 136.09, 135.09, 131.78, 127.96,
122.02, 116.89 (t, J = 4.3 Hz), 105.70–120.02 (m, Rf8), 35.14 (t,
J = 22.8 Hz).
MS (EI, 70 eV): m/z (%) = 615.0 (7) [M+], 535.8 (1), 168.9 (100).
1-(4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,11-Heptadecafluoroundec-
1-enyl)-4-iodobenzene (4c)
As described for 4a using 3b (6.0 g, 13.04 mmol), 4-iodobenzene-
diazonium tetrafluoroborate (4.14 g, 13.04 mmol), Pd(OAc)2 (58
mg, 0.26 mmol), MeOH (20 mL), and THF (5 mL), NaOAc (8.1 g,
9.89 mmol), and MeCN (140 mL) at 40 °C for 18 h gave 4c (3.0 g,
35%); Rf = 0.54 (pentane).
1H NMR (360 MHz, CDCl3): d = 7.66 (d, J = 8.4 Hz, 2 H, Ar), 7.12
(d, J = 8.4 Hz, 2 H, Ar), 6.55 (d, J = 15.4 Hz, 1 H, CH), 6.15 (dt,
J = 15.4, 7.5 Hz, 1 H, CH), 3.00 (dt, J = 17.7, 7.5 Hz, 2 H, CH).
13C NMR (90.55 MHz, CDCl3): d = 137.76, 136.22, 135.67, 128.17,
117.03 (t, J = 4.3 Hz), 105.70–120.02 (m, Rf8), 93.56, 35.16 (t,
J = 22.8 Hz).
ht
tp
://
do
c.
re
ro
.c
h
8
MS (EI, 70 eV): m/z (%) = 663.1 (7) [M+], 535.8 (1), 115.7 (100).
1-Iodo-4-(4,4,5,5,6,6,7,7,8,8,9,9,9-tridecafluorononyl)benzene 
(5a); Typical Procedure
Iodoaryl 4a (6.4 g, 11.4 mmol) was dissolved in CH2Cl2 (15 mL)
and added to a 200-mL autoclave. After the addition of pentane (50
mL), argon was bubbled through the mixture for 10 min before
Rh/C (5% Rh, 929 mg, 0.456 mmol) was added. The autoclave was
then tightly closed and purged with H2 (3 × 50 bar). The mixture
was then stirred at r.t. under H2 (60 bar) for 28 h. The suspension
was filtered through a plug of silica gel (pentane); removal of all
volatiles gave 5a (6.3 g, 98%) as a white solid; Rf = 0.66 (pentane).
1H NMR (360 MHz, CDCl3): d = 7.64 (d, J = 8.2 Hz, 2 H, Ar), 6.96
(d, J = 8.2 Hz, 2 H, Ar), 2.67 (t, J = 7.5 Hz, 2 H, CH2), 2.00–2.18
(m, 2 H, CH2), 1.93 (quint, J = 7.5 Hz, 2 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 140.20, 137.65, 130.40,
107.69–121.51 (m, Rf6), 91.41, 34.49, 30.20 (t, J = 22.5 Hz), 21.66
(t, J = 3.3 Hz).
MS (EI, 70 eV): m/z (%) = 564.8 (42) [M+], 437.5 (1), 217.0 (100).
1-(4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,11-Heptadecafluoro-
undecyl)-4-iodobenzene (5b); Typical Procedure
Ni (6.2 g, 10.6 mmol), KI (7.0 g, 42.2 mmol), and I2 (268 mg, 1.1
mmol) were charged into a Schlenk reaction vessel and suspended
in DMF (30 mL) under an inert atmosphere. Compound 6a (13.0 g,
21.0 mmol) was degassed in a separate flask, diluted with DMF (30
mL) and added to the mixture which was then heated to 150 °C for
27 h. The dark brown mixture was, after cooling to r.t., decanted off
from the nickel residue. The crude product was extracted with pen-
tane (3 × 100 mL) and the combined organic fractions were washed
with H2O (100 mL), 3% HCl (50 mL), and H2O (100 mL), and dried
(Na2SO4). Removal of all volatiles gave 5b as a yellow crystalline
solid. Purification was completed by filtration through a plug of sil-
ica gel (pentane) under reduced pressure to give 5b (13.7 g, 99%) as
a white crystalline solid; Rf = 0.54 (pentane).
1H NMR (360 MHz, CDCl3): d = 7.63 (d, J = 8.2 Hz, 2 H, Ar), 6.94
(d, J = 8.2 Hz, 2 H, Ar), 2.65 (t, J = 7.5 Hz, 2 H, CH2), 1.95–2.14
(m, 2 H, CH2), 1.91 (quint, J = 7.5 Hz, 2 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 140.22, 137.66, 130.40,
107.74–120.13 (m, Rf8), 91.41, 34.51, 30.21 (t, J = 22.5 Hz), 21.68
(t, J = 3.3 Hz).
MS (EI, 70 eV): m/z (%) = 665.1 (15) [M+], 537.8 (1), 217.0 (100).
1-Iodo-4-(5,5,6,6,7,7,8,8,8-nonafluorooctyl)benzene (5c)
As described for 5b using 9a (5.5 g, 12.75 mmol), Ni (3.74 g, 63.78
mmol), KI (4.23 g, 25.51 mmol), I2 (160 mg, 0.63 mmol), and DMF
(35 mL) gave 5c (4.71 g, 77%); Rf = 0.85 (pentane).
1H NMR (360 MHz, CDCl3): d = 7.60 (d, J = 8.2 Hz, 2 H, Ar), 7.04
(d, J = 8.2 Hz, 2 H, Ar), 2.59 (t, J = 7.3 Hz, 2 H, CH2), 1.99–2.16
(m, 2 H, CH2), 1.62–1.67 (m, 4 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 141.24, 137.47, 130.44,
108.55–122.20 (m, Rf4), 90.98, 35.03, 30.58 (t, J = 22.5 Hz), 30.06,
19.72 (t, J = 3.3 Hz).
MS (EI, 70 eV): m/z (%) = 478.6 (45) [M+], 217.0 (100).
1-(5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,14-Heni-
cosafluorotetradecyl)-4-iodobenzene (5d)
As described for 5b using 9b (6.0 g, 8.2 mmol), Ni (2.4 g, 41.0
mmol), KI (2.7 g, 16.4 mmol), I2 (104 mg, 0.4 mmol), and DMF (25
mL) gave 5d (4.8 g, 75%); Rf = 0.90 (pentane).
1H NMR (360 MHz, CDCl3): d = 7.60 (d, J = 8.2 Hz, 2 H, Ar), 6.92
(d, J = 8.2 Hz, 2 H, Ar), 2.59 (t, J = 6.8 Hz, 2 H, CH2), 2.01–2.16
(m, 2 H, CH2), 1.64–1.75 (m, 4 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 141.26, 137.50, 130.44,
107.79–121.91 (m, Rf10), 90.98, 35.05, 30.67, 30.67 (t, J = 21.8
Hz), 19.77 (t, J = 3.5 Hz).
MS (EI, 70 eV): m/z (%) = 777.9 (95) [M+], 216.9 (100).
1-Bromo-4-(6,6,7,7,8,8,9,9,10,10,11,11,11-tridecafluoro-
undecyl)benzene (5e)
As described for 5a using alkyne 12a (4.8 g, 8.9 mmol), Rh/C (300
mg), pentane (45 mL), and CH2Cl2 (15 mL) gave 5e (4.61 g, 95%);
Rf = 0.85 (pentane).
1H NMR (360 MHz, CDCl3): d = 7.40 (d, J = 8.2 Hz, 2 H, Ar), 7.04
(d, J = 8.2 Hz, 2 H, Ar), 2.58 (t, J = 7.7 Hz, 2 H, CH2), 1.97–2.11
(m, 2 H, CH2), 1.60–1.68 (m, 4 H, CH2), 1.36–1.43 (m, 2 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 141.06, 131.39, 130.12, 119.53,
105.33–118.80 (m, Rf6), 35.01, 30.86, 30.79 (t, J = 22.5 Hz), 28.54,
19.99 (t, J = 3.3 Hz).
MS (EI, 70 eV): m/z (%) = 544.9 (8) [M+], 168.9 (100), 91.0 (27).
1-Bromo-4-(7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,14-hepta-
decafluorotetradecyl)benzene (5f)
As described for 5a using alkyne 12b (2.0 g, 3.1 mmol), Rh/C (100
mg), pentane (18 mL), and CH2Cl2 (6 mL) gave 5f (2.0 g, 99%);
Rf = 0.65 (pentane).
1H NMR (360 MHz, CDCl3): d = 7.39 (d, J = 8.2 Hz, 2 H, Ar), 7.04
(d, J = 8.2 Hz, 2 H, Ar), 2.56 (t, J = 7.7 Hz, 2 H, CH2), 1.96–2.11
(m, 2 H, CH2), 1.56–1.65 (m, 4 H, CH2), 1.34–1.42 (m, 4 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 141.39, 131.32, 130.12, 119.40,
107.69–118.71 (m, Rf8), 35.19, 30.99, 30.83 (t, J = 22.5 Hz), 28.92,
28.72, 20.03 (t, J = 3.3 Hz).
MS (EI, 70 eV): m/z (%) = 659.3 (6) [M+], 168.9 (100), 91.0 (24).
1-Bromo-4-(9,9,10,10,11,11,12,12,12-nonafluorododecyl)ben-
zene (5g)
As described for 5a using alkyne 12c (2.4 g, 4.96 mmol), Rh/C (150
mg), pentane (18 mL), and CH2Cl2 (6 mL) gave 5g (2.34 g, 97%);
Rf = 0.91 (pentane).
1H NMR (360 MHz, CDCl3): d = 7.39 (d, J = 8.2 Hz, 2 H, Ar), 7.05
(d, J = 8.2 Hz, 2 H, Ar), 2.56 (t, J = 7.7 Hz, 2 H, CH2), 1.97–2.12
(m, 2 H, CH2), 1.54–1.60 (m, 4 H, CH2), 1.28–1.39 (m, 8 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 141.67, 131.26, 130.15, 119.29,
105.35–120.77 (m, Rf4), 35.29, 31.26, 30.75 (t, J = 22.5 Hz), 29.02,
29.98, 29.15, 29.17, 20.03 (t, J = 3.3 Hz).
MS (EI, 70 eV): m/z (%) = 488.7 (13) [M+], 168.9 (100), 91.0 (41).
1-Iodo-4-(9,9,10,10,11,11,12,12,13,13,14,14,14-tridecafluoro-
tetradecyl)benzene (5h)
As described for 5b using 13a (2.1 g, 3.6 mmol), Ni (1.05 g, 17.9
mmol), KI (1.2 g, 7.15 mmol), I2 (45 mg, 0.18 mmol), and DMF (15
mL) gave 5h (2.0 g, 88%); Rf = 0.90 (pentane).
1H  NMR (360 MHz, CDCl3): d = 7.58 (d, J = 8.2 Hz, 2 H, Ar), 6.92
(d, J = 8.2 Hz, 2 H, Ar), 2.54 (t, J = 7.3 Hz, 2 H, CH2), 1.96–2.11
(m, 2 H, CH2), 1.54–1.60 (m, 4 H, CH2), 1.28–1.39 (m, 8 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 142.78, 137.67, 130.94, 90.94,
105.79–119.70 (m, Rf6), 35.79, 31.60, 31.26 (t, J = 22.5 Hz), 29.45,
29.47, 29.50, 29.52, 20.47 (t, J = 3.3 Hz). 
MS (EI, 70 eV): m/z (%) = 635.2 (16) [M+], 217.0 (100), 90.9 (29).
1-(9,9,10,10,11,11,12,12,13,13,14,14,15,15,16,16,16-Heptadeca-
fluorohexadecyl)-4-iodobenzene (5i)
As described for 5b using 13b (4.1 g, 5.9 mmol), Ni (1.75 g, 29.8
mmol), KI (2.0 g, 11.9 mmol), I2 (76 mg, 0.30 mmol), and DMF (20
mL) gave 5i (3.96 g, 90%); Rf = 0.85 (pentane).
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1H NMR (360 MHz, CDCl3): d = 7.58 (d, J = 8.2 Hz, 2 H, Ar), 6.92
(d, J = 8.2 Hz, 2 H, Ar), 2.54 (t, J = 7.3 Hz, 2 H, CH2), 1.96–2.09
(m, 2 H, CH2), 1.54–1.59 (m, 4 H, CH2), 1.28–1.39 (m, 8 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 142.78, 137.67, 130.94,
105.79–119.70 (m, Rf8), 90.94, 35.79, 31.61, 31.26 (t, J = 22.5 Hz),
29.45–29.52 (4C), 20.47 (t, J = 3.3 Hz). 
MS (EI, 70 eV): m/z (%) = 735.4 (8) [M+], 217.0 (100), 91.0 (24).
1-Bromo-4-(4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,11-heptadeca-
fluoroundecyl)benzene (6a)
As described for 5a using alkene 4b (14.0 g, 23.0 mmol), Rh/C (702
mg), pentane (60 mL), and CH2Cl2 (20 mL) gave (13.9 g, 98%);
Rf = 0.54 (pentane).
1H NMR (360 MHz, CDCl3): d = 7.43 (d, J = 8.2 Hz, 2 H, Ar), 7.06
(d, J = 8.2 Hz, 2 H, Ar), 2.67 (t, J = 7.5 Hz, 2 H, CH2), 2.0–2.14 (m,
2 H, CH2), 1.92 (quint, J = 7.5 Hz, 2 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 139.55, 131.68, 130.06, 120.13,
107.78–122.29 (m, Rf8), 34.41, 30.21 (t, J = 22.5 Hz), 21.71 (t,
J = 3.3 Hz).
MS (EI, 70 eV): m/z (%) = 617.0 (15) [M+], 537.8 (1), 170.8 (100).
1-Bromo-4-(5,5,6,6,7,7,8,8,8-nonafluoro-3-iodooctyl)benzene 
(8a)
1-Bromo-4-but-3-enylbenzene (7, 17 g, 80.53 mmol) was added to
a round-bottomed flask and heated to 50 °C; 30% aq Na2S2O5 soln
(7.6 mL) and perfluorobutyl iodide (27 g, 78.45 mmol) were added.
Under a positive stream of argon AIBN (230 mg, 1.39 mmol) was
added and the mixture was heated to 80 °C for 2 h. The mixture was
allowed to reach r.t. and then H2O (50 mL) was added. The obtained
suspension was extracted with Et2O (3 × 100 mL). The combined
organic phases were washed with H2O (50 mL) and dried (Na2SO4)
and all volatiles were removed under reduced pressure to give 8a
(31.1 g, 71%) as a colorless oil; Rf = 0.85 (pentane).
1H NMR (360 MHz, CDCl3): d = 7.38 (d, J = 8.6 Hz, 2 H, Ar), 7.09
(d, J = 8.6 Hz, 2 H, Ar), 4.23 (tt, J = 8.2, 5.0 Hz, 1 H, CH), 2.67–
3.02 (m, 2 H, CH2), 2.66 (t, J = 8.2 Hz, 2 H, CH2), 2.02–2.16 (m, 2
H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 138.76, 131.68, 130.22, 120.21,
108.40–122.40 (m, Rf4), 41.57 (t, J = 22.5 Hz), 41.38, 35.12, 19.65
(t, J = 2.5 Hz).
MS (EI, 70 eV): m/z (%) = 556.7 (8) [M+], 429.5 (12), 168.9 (100).
1-Bromo-4-(5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,14-
henicosafluoro-3-iodo-tetradecyl)benzene (8b)
As described for 8a using 7 (4.45 g, 21.1 mmol), perfluorodecyl io-
dide (15.0 g, 23.2 mmol), AIBN (70 mg, 0.42 mmol), and 30%
Na2S2O5 (5 mL) gave 8b (17.7 g, 98%); Rf = 0.91 (pentane).
1H NMR (360 MHz, CDCl3): d = 7.43 (d, J = 8.2 Hz, 2 H, Ar), 7.09
(d, J = 8.2 Hz, 2 H, Ar), 4.23 (tt, J = 8.6, 5.0 Hz, 1 H, CH), 2.65–
3.04 (m, 2 H, CH2), 2.65–2.73 (m, 2 H, CH2), 2.05–2.12 (m, 2 H,
CH2).
13C NMR (90.55 MHz, CDCl3): d = 138.78, 131.70, 130.24, 120.21,
108.37–121.10 (m, Rf10), 41.71 (t, J = 21.1 Hz), 41.42, 35.14,
19.74.
MS (EI, 70 eV): m/z (%) = 857.5 (1) [M+], 730.3 (4), 168.9 (100).
1-Bromo-4-(5,5,6,6,7,7,8,8,8-nonafluorooctyl)benzene (9a); 
Typical Procedure
LiAlH4 (1.8 g, 47.4 mmol) was placed in a 500-mL 3-necked flask
under inert atmosphere and THF (60 mL) was added by syringe.
Compound 8a (22 g, 39.5 mmol) was dissolved in THF (40 mL) and
was carefully added to the LiAlH4 slurry in such a rate to maintain
the reaction medium at a gentle reflux. After 6 h at r.t. the mixture
was quenched by the addition of H2O (5 mL), 15% NaOH (5 mL),
and H2O (15 mL). The crude reaction product was extracted with
Et2O (3 × 200 mL). The combined organic phases were filtered
through a Büchner and the filtrate was washed with H2O (50 mL)
and dried (Na2SO4) and all volatiles were removed under reduced
pressure yielding 9a (13.6 g, 80%) as a colorless oil; Rf = 0.85 (pen-
tane).
1H NMR (360 MHz, CDCl3): d = 7.37 (d, J = 8.6 Hz, 2 H, Ar), 7.04
(d, J = 8.6 Hz, 2 H, Ar), 2.58 (t, J = 6.8 Hz, 2 H, CH2), 2.00–2.13
(m, 2 H, CH2), 1.58–1.69 (m, 4 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 140.53, 131.46, 130.05, 119.7,
107.19–121.07 (m, Rf4), 35.11, 30.64, 30.54 (t, J = 22.5 Hz), 19.69
(t, J = 3.3 Hz). 
MS (EI, 70 eV): m/z (%) = 430.5 (12) [M+], 168.9 (100).
1-Bromo-4-(5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,14-
henicosafluorotetradecyl)benzene (9b)
As described for 9a using aryl 8b (18.0 g, 21.0 mmol), LiAlH4 (797
mg, 21 mmol), and THF (50 mL) gave 9b (6.2 g, 40%); Rf = 0.80
(pentane).
1H NMR (360 MHz, CDCl3): d = 7.41 (d, J = 8.2 Hz, 2 H, Ar), 7.04
(d, J = 8.2 Hz, 2 H, Ar), 2.61 (t, J = 6.8 Hz, 2 H, CH2), 2.00–2.17
(m, 2 H, CH2), 1.63–1.76 (m, 4 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 140.54, 131.48, 130.08, 119.72,
107.77–121.88 (m, Rf10), 34.94, 30.69, 30.69 (t, J = 21.1 Hz), 19.75
(t, J = 4.0 Hz).
MS (EI, 70 eV): m/z (%) = 731.8 (80) [M+], 170.9 (100).
6,6,7,7,8,8,9,9,10,10,11,11,11-Tridecafluoroundec-1-yne (11a); 
Typical Procedure
Lithium acetylide–ethylenediamine complex (18.2 g, 0.20 mol) was
suspended in DMSO (90 mL) in a round-bottomed flask under an
inert atmosphere. To the brown-colored suspension 9-bromo-
1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorononane (10a, 29 g, 65.7
mmol) dissolved in pentane (10 mL) was added at 8 °C. The black
suspension was stirred at r.t. for 17 h and the mixture was quenched
by the addition of H2O (30 mL). The resulting suspension was dilut-
ed with CH2Cl2 (100 mL), Büchner filtered, and extracted with
CH2Cl2 (3 × 100 mL). The  combined organic phases were dried
(Na2SO4) and all volatiles were removed under reduced pressure.
The resulting black oily liquid was filtered over a plug of silica gel
under reduced pressure (pentane). After removal of pentane the title
compound (9.64 g, 38%) was obtained as colorless oil; Rf = 0.95
(pentane).
1H NMR (360 MHz, CDCl3): d = 2.33 (td, J = 6.8, 2.7 Hz, 2 H,
CH2), 2.16–2.28 (m, 2 H, CH2), 2.02 (t, J = 2.7 Hz, 1 H, CH), 1.78–
1.89 (m, 2 H, CH2). 
13C NMR (90.55 MHz, CDCl3): d = 108.10–121.18 (m, Rf6), 82.27,
79.72, 29.83 (t, J = 22.5 Hz), 19.34 (t, J = 3.3 Hz), 17.91.
MS (EI, 70 eV): m/z (%) = 117.0 (15), 66.9 (100).
7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,14-Heptadecafluoro-
tetradec-1-yne (11b)
As described for 11a using 12-bromo-
1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8-heptadecafluorododecane (10b,
15.0 g, 25.2 mmol), lithium acetylide–ethylenediamine complex
(7.0 g, 75.6 mmol), DMSO (30 mL), and pentane (15 mL) gave 11b
(4.94 g, 39%); Rf = 0.90 (pentane).
1H NMR (360 MHz, CDCl3): d = 2.25 (td, J = 6.8, 2.7 Hz, 2 H,
CH2), 2.02–2.17 (m, 2 H, CH2), 1.98 (t, J = 2.7 Hz, 1 H, CH), 1.71–
1.80 (m, 2 H, CH2), 1.59–1.67 (m, 2 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 107.43–121.94 (m, Rf8), 83.27,
68.94, 30.44 (t, J = 22.5 Hz), 27.76, 19.34 (t, J = 3.3 Hz), 18.13.
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MS (EI, 70 eV): m/z (%) = 500.8 (2) [M+], 131.0 (42), 81.0 (100).
9,9,10,10,11,11,12,12,12-Nonafluorododec-1-yne (11c)
As described for 11a using 10-bromo-1,1,1,2,2,3,3,4,4-nonafluoro-
decane (10c, 24.0 g, 62.6 mmol), lithium acetylide–ethylenedi-
amine complex (17.3 g, 0.19 mol), DMSO (100 mL), and pentane
(10 mL) gave 11c (12.8 g, 62%); Rf = 0.99 (pentane).
1H NMR (360 MHz, CDCl3): d = 2.21 (td, J = 7.0, 2.7 Hz, 2 H,
CH2), 2.01–2.15 (m, 2 H, CH2), 1.95 (t, J = 2.7 Hz, 1 H, CH), 1.59–
1.67 (m, 2 H, CH2), 1.52–1.59 (m, 2 H, Hz, CH2), 1.39–1.52 (m, 4
H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 106.03–123.20 (m, Rf4), 84.27,
68.32, 30.71 (t, J = 22.5 Hz), 28.56, 28.24, 28.11, 19.97 (t, J = 3.3
Hz), 18.27.
MS (EI, 70 eV): m/z (%) = 95.0 (25), 81.4 (100), 67.0 (76).
9,9,10,10,11,11,12,12,13,13,14,14,14-Tridecafluorotetradec-1-
yne (11d)
As described for 11a using 12-bromo-1,1,1,2,2,3,3,4,4,5,5,6,6-
tridecafluorododecane (10d, 12.0 g, 24.8 mmol), lithium acetylide–
ethylenediamine complex (16.9 g, 0.18 mol), DMSO (30 mL), and
pentane (20 mL) gave 11d (7.72 g, 73%); Rf = 0.84 (silica gel, pen-
tane, KMnO4).
1H NMR (360 MHz, CDCl3): d = 2.21 (td, J = 7.0, 2.7 Hz, 2 H,
CH2), 2.00–2.15 (m, 2 H, CH2), 1.96 (t, J = 2.7 Hz, 1 H, CH), 1.59–
1.67 (m, 2 H, CH2), 1.52–1.59 (m, 2 H, CH2), 1.39–1.52 (m, 4 H,
CH2).
13C NMR (90.55 MHz, CDCl3): d = 103.61–121.66 (m, Rf6), 84.30,
68.34, 30.81 (t, J = 22.5 Hz), 28.56, 28.24, 28.11, 20.00 (t, J = 3.3
Hz), 18.28.
MS (EI, 70 eV): m/z (%) = 95.1 (33), 81.1 (100), 67.1 (36).
9,9,10,10,11,11,12,12,13,13,14,14,15,15,16,16,16-Heptadeca-
fluorohexadec-1-yne (11e)
As described for 11a using 14-bromo-
1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8-heptadecafluorotetradecane (10e,
14.1 g, 24.2 mmol), lithium acetylide ethylenediamine complex (6.7
g, 72.6 mmol), DMSO (40 mL), and pentane (30 mL) gave (5.6 g,
44%); Rf = 0.80 (pentane).
1H NMR (360 MHz, CDCl3): d = 2.21 (td, J = 7.0, 2.7 Hz, 2 H,
CH2), 2.00–2.15 (m, 2 H, CH2), 1.95 (t, J = 2.7 Hz, 1 H, CH), 1.59–
1.67 (m, 2 H, CH2), 1.52–1.59 (m, 2 H, CH2), 1.40–1.52 (m, 4 H,
CH2).
13C NMR (90.55 MHz, CDCl3): d = 107.80–118.72 (m, Rf8), 84.30,
68.34, 30.82 (t, J = 22.5 Hz), 28.56, 28.24, 28.11, 20.00 (t, J = 3.3
Hz), 18.28.
MS (EI, 70 eV): m/z (%) = 131.0 (43), 81.0 (100), 67.0 (30).
1-Bromo-4-(6,6,7,7,8,8,9,9,10,10,11,11,11-tridecafluoroundec-
1-ynyl)benzene (12a); Typical Procedure
Pd(PPh3)4 (1.65 g, 1.43 mmol), CuI (453 mg, 2.38 mmol), and 1-
bromo-4-iodobenzene (6.74 g, 23.8 mmol) were dissolved in THF
(110 mL) in a Schlenk reaction vessel under an inert atmosphere.
Compound 11a (9.2 g, 23.8 mmol) was degassed in a separate flask,
diluted with THF (20 mL), and added into the Schlenk flask, and
then Et3N (20.0 mL, 143 mmol) was added by syringe. The Schlenk
tube was sealed and heated to 80 °C for 6 d. The cold mixture was
then quenched by the addition of H2O (100 mL) and extracted with
Et2O (3 × 100 mL). The combined organic fractions were washed
with 10% HCl (150 mL) and H2O (100 mL) and dried (Na2SO4) and
all volatiles were removed yielding a brown oil. Several filtrations
through silica gel (pentane–Et2O, 9:1 then pentane for successive
filtrations) yielded 12a (4.91 g, 38%) as a colorless oil; Rf = 0.78
(pentane).
1H NMR (360 MHz, CDCl3): d = 7.42 (d, J = 8.2 Hz, 2 H, Ar), 7.25
(d, J = 8.2 Hz, 2 H, Ar), 2.53 (t, J = 6.8 Hz, 2 H, CH2), 2.20–2.34
(m, 2 H, CH2), 1.88–1.96 (m, 2 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 133.01, 131.51, 122.35, 122.06,
107.70–118.79 (m, Rf6), 89.06, 81.00, 30.06 (t, J = 22.5 Hz), 19.58
(t, J = 3.3 Hz), 18.94.
MS (EI, 70 eV): m/z (%) = 540.9 (32) [M+], 461.7 (8), 223.1 (17),
192.9 (100), 172.0 (45), 142 (63), 128.0 (63).
1-Bromo-4-(7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,14-hepta-
decafluorotetradec-1-ynyl)benzene (12b)
As described for 12a using alkyne 11b (4.8 g, 9.6 mmol), Pd(PPh3)4
(670 mg, 0.57 mmol), CuI (183 mg, 0.96 mmol), 1-bromo-4-iodo-
benzene (2.7 g, 9.6 mmol), Et3N (8.0 mL, 57.6 mmol), and THF (50
mL) gave 12b (2.27 g, 36%); Rf = 0.62 (pentane).
1H NMR (360 MHz, CDCl3): d = 7.41 (d, J = 8.2 Hz, 2 H, Ar), 7.24
(d, J = 8.2 Hz, 2 H, Ar), 2.46 (t, J = 6.8 Hz, 2 H, CH2), 2.06–2.20
(m, 2 H, CH2), 1.75–1.84 (m, 2 H, CH2), 1.66–1.74 (m, 2 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 132.99, 131.46, 122.65, 121.82,
107.74–119.07 (m, Rf8), 90.16, 80.36, 30.45 (t, J = 22.5 Hz), 27.89,
19.50 (t, J = 3.3 Hz), 19.13.
MS (EI, 70 eV): m/z (%) = 655.2 (12) [M+], 576.1 (16), 221.0 (27),
192.9 (90), 142 (100), 128.0 (83).
1-Bromo-4-(9,9,10,10,11,11,12,12,12-nonafluorododec-1-
ynyl)benzene (12c)
As described for 12a using alkyne 11c (10.1 g, 30.7 mmol),
Pd(PPh3)4 (1.4 g, 1.2 mmol), CuI (470 mg, 2.5 mmol), 1-bromo-4-
iodobenzene (8.7 g, 30.7 mmol), Et3N (25.6 mL, 0.18 mol), and
THF (120 mL) gave 12c (11.6 g, 78%); Rf = 0.81  (pentane).
1H NMR (360 MHz, CDCl3): d = 7.42 (d, J = 8.2 Hz, 2 H, Ar), 7.26
(d, J = 8.2 Hz, 2 H, Ar), 2.42 (t, J = 6.8 Hz, 2 H, CH2), 2.01–2.16
(m, 2 H, CH2), 1.59–1.69 (m, 4 H, CH2), 1.45–1.53 (m, 4 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 132.99, 131.42, 122.90, 121.64,
108.54–121.07 (m, Rf4), 91.23, 79.82, 30.72 (t, J = 22.5 Hz), 28.61,
28.45, 28.27, 20.00 (t, J = 3.3 Hz), 19.31.
MS (EI, 70 eV): m/z (%) = 484.7 (9) [M+], 237.1 (8), 223.1 (22),
209.0 (6), 194.9 (65), 181.8 (12), 168.9 (8), 142 (100).
1-Bromo-4-(9,9,10,10,11,11,12,12,13,13,14,14,14-tridecafluo-
rotetradec-1-ynyl)benzene (12d)
As described for 12a using alkyne 11d (5.5 g, 12.8 mmol),
Pd(PPh3)4 (890 mg, 0.77 mmol), CuI (245 mg, 1.28 mmol), 1-bro-
mo-4-iodobenzene (3.6 g, 12.8 mmol), Et3N (10.75 mL, 77.0
mmol), and THF (65 mL) gave 12d (2.63 g, 35%); Rf = 0.86 (pen-
tane).
1H NMR (360 MHz, CDCl3): d = 7.42 (d, J = 8.2 Hz, 2 H, Ar), 7.26
(d, J = 8.2 Hz, 2 H, Ar), 2.42 (t, J = 6.8 Hz, 2 H, CH2), 2.01–2.16
(m, 2 H, CH2), 1.59–1.70 (m, 4 H, CH2), 1.45–1.55 (m, 4 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 132.99, 131.42, 122.90, 121.64,
107.22–119.17 (m, Rf6), 91.23, 79.83, 30.83 (t, J = 22.5 Hz), 28.62,
28.45, 28.29, 20.03 (t, J = 3.3 Hz), 19.32.
MS (EI, 70 eV): m/z (%) = 584.9 (7) [M+], 237.1 (8), 223.1 (35),
209.0 (6), 194.9 (84), 181.8 (12), 168.9 (18), 142 (100).
1-Bromo-4-(9,9,10,10,11,11,12,12,13,13,14,14,15,15,16,16,16-
heptadecafluorohexadec-1-ynyl)benzene (12e)
As described for 12a using alkyne 11e (5.5 g, 10.4 mmol),
Pd(PPh3)4 (720 mg, 0.62 mmol), CuI (198 mg, 1.04 mmol), 1-bro-
mo-4-iodobenzene (2.9 g, 10.4 mmol), Et3N (8.7 mL, 62.5 mmol),
and THF (70 mL) gave 12e (2.46 g, 35%); Rf = 0.79 (pentane).
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1H NMR (360 MHz, CDCl3): d = 7.42 (d, J = 8.2 Hz, 2 H, Ar), 7.25
(d, J = 8.2 Hz, 2 H, Ar), 2.41 (t, J = 6.8 Hz, 2 H, CH2), 2.00–2.15
(m, 2 H, CH2), 1.59–1.69 (m, 4 H, CH2), 1.45–1.55 (m, 4 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 132.99, 131.42, 122.89, 121.64,
108.17–118.36 (m, Rf8), 91.23, 79.82, 30.82 (t, J = 22.5 Hz), 28.62,
28.45, 28.27, 20.03 (t, J = 3.3 Hz), 19.31.
MS (EI, 70 eV): m/z (%) = 685.2 (7) [M+], 237.1 (8), 223.1 (34),
209.0 (9), 194.9 (82), 181.8 (15), 168.9 (18), 142 (100).
1-Bromo-4-(9,9,10,10,11,11,12,12,13,13,14,14,14-tridecafluo-
rotetradecyl)benzene (13a)
As described for 5a using alkyne 12d (2.5 g, 4.3 mmol), Rh/C (130
mg), pentane (24 mL), and CH2Cl2 (7 mL) gave 13a (2.24 g, 89%);
Rf = 0.90 (pentane).
1H NMR (360 MHz, CDCl3): d = 7.39 (d, J = 8.2 Hz, 2 H, Ar), 7.05
(d, J = 8.2 Hz, 2 H, Ar), 2.56 (t, J = 7.7 Hz, 2 H, CH2), 1.98–2.13
(m, 2 H, CH2), 1.56–1.60 (m, 4 H, CH2), 1.27–1.38 (m, 8 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 141.67, 131.27, 130.15, 119.29,
105.35–120.77 (m, Rf6), 35.30, 31.23, 30.85 (t, J = 22.5 Hz, 29.05,
29.08, 29.10, 29.11, 20.07 (t, J = 3.3 Hz).
MS (EI, 70 eV): m/z (%) = 589.7 (9) [M+], 170.9 (100), 90.9 (33).
1-Bromo-4-(9,9,10,10,11,11,12,12,13,13,14,14,15,15,16,16,16-
heptadecafluorohexadecyl)benzene (13b)
As described for 5a using alkyne 12e (4.5 g, 6.6 mmol), Rh/C (200
mg), pentane (21 mL), and CH2Cl2 (7 mL) gave 13b (4.21 g, 93%);
Rf = 0.85 (pentane).
1H NMR (360 MHz, CDCl3): d = 7.39 (d, J = 8.2 Hz, 2 H, Ar), 7.05
(d, J = 8.2 Hz, 2 H, Ar), 2.56 (t, J = 7.7 Hz, 2 H, CH2), 1.98–2.13
(m, 2 H, CH2), 1.56–1.60 (m, 4 H, CH2), 1.27–1.39 (m, 8 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 142.08, 131.67, 130.55, 119.70,
106.40–118.86 (m, Rf8), 35.70, 31.64, 31.26 (t, J = 22.5 Hz), 29.45,
29.49, 29.53, 29.58, 20.47 (t, J = 3.3 Hz).
MS (EI, 70 eV): m/z (%) = 689.3 (9) [M+], 170.8 (100), 90.9 (33).
1-(4,4,5,5,6,6,7,7,8,8,9,9,9-Tridecafluorononyl)-4-{[4-
(4,4,5,5,6,6,7,7,8,8,9,9,9-tridecafluorononyl)phenyl]eth-
ynyl}benzene (14a); Typical Procedure
CuI (209 mg, 1.1 mmol) and PdCl2(PPh3)2 (463 mg, 0.66 mmol)
were suspended in THF (10 mL) in an oven dried Schlenk reaction
vessel under an inert atmosphere. Iodoaryl 5a (6.2 g, 11.0 mmol)
was dissolved in THF (10 mL) and degassed separately then added
into the reaction vessel. Degassed DBU (9.9 mL, 65.9 mmol) was
added via syringe into the Schlenk and the reaction medium was
purged with argon. H2O (79 mL, 4.4 mmol) and cooled (4 °C) tri-
methylsilylacetylene (0.8 mL, 5.5 mmol) were added simultaneous-
ly with two syringes. The Schlenk was then covered with aluminum
foil and heated to 75 °C. After 29 h, the black mixture was washed
with H2O (2 × 100 mL), 10% HCl (50 mL), brine (50 mL), and H2O
(50 mL). The combined organic fractions were purified by several
precipitations (Et2O–pentane–EtOH) to yield 14a (3.0 g, 61%) as a
white solid; Rf = 0.42 (pentane).
1H NMR (360 MHz, CDCl3): d = 7.47 (d, J = 8.2 Hz, 4 H, Ar), 7.17
(d, J = 8.2 Hz, 4 H, Ar), 2.73 (t, J = 7.3 Hz, 4 H, CH2), 1.91–2.17
(m, 8 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 140.88, 131.81, 128.39, 121.32,
105.69–120.49 (m, Rf6), 89.01, 34.90, 30.23 (t, J = 22.5 Hz), 21.63
(t, J = 3.3 Hz).
MS (EI, 70 eV): m/z (%) = 900.0 (11) [M+], 551.9 (100).
1-(4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,11-Heptadecafluoro-
undecyl)-4-{[4-(4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,11-heptadeca-
fluoroundecyl)phenyl]ethynyl}benzene (14b)
As described for 14a using iodoaryl 5b (5.0 g, 7.7 mmol),
PdCl2(PPh3)2 (530 mg, 0.46 mmol), CuI (146 mg, 0.77 mmol), DBU
(6.9 mL, 45.2 mmol), THF (40 mL), H2O (55 mL, 3.1 mmol), and
trimethylsilylacetylene (0.56 mL, 3.8 mmol) gave 14b (2.71 g,
66%); Rf = 0.90 (pentane–Et2O, 9:1).
1H NMR (360 MHz, CDCl3): d = 7.47 (d, J = 8.2 Hz, 4 H, Ar), 7.17
(d, J = 8.2 Hz, 4 H, Ar), 2.73 (t, J = 7.5 Hz, 4 H, CH2), 1.95–2.14
(m, 8 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 140.87, 131.80, 128.39, 121.30,
107.74–120.13 (m, Rf8), 89.01, 34.89, 30.23 (t, J = 22.5 Hz), 21.63
(t, J = 3.3 Hz).
MS (MALDI-ICR, DCTB): m/z (%) = 1349.27 (80) [M + DCTB]+,
1098.10 (100) [M+].
1-(5,5,6,6,7,7,8,8,8-Nonafluorooctyl)-4-{[4-(5,5,6,6,7,7,8,8,8-
nonafluorooctyl)phenyl]ethynyl}benzene (14c)
As described for 14a using iodoaryl 5c (11.2 g, 26.0 mmol),
PdCl2(PPh3)2 (1.09 g, 1.56 mmol), CuI (496 mg, 2.6 mmol), DBU
(23.3 mL, 156.2 mmol), THF (125 mL), H2O (190 mL, 10.4 mmol),
and trimethylsilylacetylene (1.9 mL, 13.0 mmol) gave 14c (1.9 g,
20%); Rf = 0.82 (pentane–Et2O, 9:1).
1H NMR (360 MHz, CDCl3): d = 7.45 (d, J = 8.2 Hz, 4 H, Ar), 7.15
(d, J = 8.2 Hz, 4 H, Ar), 2.67 (t, J = 7.3 Hz, 4 H, CH2), 2.01–2.17
(m, 4 H, CH2), 1.62–1.76 (m, 8 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 141.89, 131.64, 128.38,
110.50–125.52 (m, Rf4), 120.94, 88.96, 35.44, 30.62, 30.62 (t,
J = 22.5 Hz), 19.75 (t, J = 3.3 Hz).
MS (EI, 70 eV): m/z (%) = 727.5 (20) [M+], 465.7 (100).
1-(5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,14-Heni-
cosafluorotetradecyl)-4-{[4-
(5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,14-heni-
cosafluorotetradecyl)phenyl]ethynyl}benzene (14d)
As described for 14a using iodoaryl 5d (3.25 g, 4.8 mmol),
PdCl2(PPh3)2 (203 mg, 0.29 mmol), CuI (92 mg, 0.48 mmol), DBU
(4.3 mL, 29.0 mmol), THF (40 mL), H2O (35 mL, 1.9 mmol), and
trimethylsilylacetylene (0.35 mL, 2.4 mmol) gave 14d (2.15 g,
80%); Rf = 0.60 (pentane–Et2O, 1:1).
1H NMR (360 MHz, CDCl3): d = 7.45 (d, J = 7.7 Hz, 4 H, Ar), 7.15
(d, J = 7.7 Hz, 4 H, Ar), 2.67 (t, J = 6.8 Hz, 4 H, CH2),  2.01–2.16
(m, 4 H, CH2), 1.64–1.75 (m, 8 H, CH2).
13C NMR (125.77 MHz, CDCl3): d = 141.89, 131.73, 128.37,
121.28, 107.79–121.91 (m, Rf10), 89.08, 35.47, 30.97 (t, J = 22.1
Hz), 30.59, 19.93.
MS (MALDI-ICR, DCTB): m/z (%) = 1577.27 (85) [M + DCTB]+,
1326.12 (100) [M+].
1-(6,6,7,7,8,8,9,9,10,10,11,11,11-Tridecafluoroundecyl)-4-{[4-
(6,6,7,7,8,8,9,9,10,10,11,11,11-tridecafluoroundecyl)phe-
nyl]ethynyl}benzene (14e)
As described for 14a using bromoaryl 5e (4.6 g, 8.4 mmol),
PdCl2(PPh3)2 (585 mg, 0.5 mmol), CuI (161 mg, 0.84 mmol), DBU
(7.6 mL, 50.6 mmol), THF (50 mL), H2O (60 mL, 3.38 mmol), and
trimethylsilylacetylene (0.74 mL, 5.1 mmol) gave 14e (225 mg,
6%); Rf = 0.95 (pentane–Et2O, 9:1).
1H NMR (360 MHz, CDCl3): d = 7.37 (d, J = 8.2 Hz, 4 H, Ar), 7.08
(d, J = 8.2 Hz, 4 H, Ar), 2.57 (t, J = 7.3 Hz, 4 H, CH2), 1.90–2.09
(m, 4 H, CH2), 1.56–1.64 (m, 8 H, CH2), 1.30–1.38 (m, 4 H, CH2).
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13C NMR (90.55 MHz, CDCl3): d = 142.45, 131.56, 128.40, 120.83,
108.10–118.79 (m, Rf6), 88.93, 35.55, 30.79, 30.79 (t, J = 22.5 Hz),
28.59, 20.00 (t, J = 3.3 Hz). 
MS (MALDI-ICR, DCTB): m/z (%) = 1205.34 (90) [M + DCTB]+,
954.18 (100) [M+].
1-(7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,14-Heptadecafluo-
rotetradecyl)-4-{[4-
(7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,14-heptadecafluo-
rotetradecyl)phenyl]ethynyl}benzene (14f)
As described for 14a using bromoaryl 5f (3.0 g, 4.6 mmol),
Pd(PPh3)4 (316 mg, 0.27 mmol), CuI (87 mg, 0.46 mmol), DBU
(4.08 mL, 27.3 mmol), THF (25 mL), H2O (32 mL, 27.3 mmol), and
trimethylsilylacetylene (0.33 mL, 2.27 mmol) gave 14f (1.2 g,
46%); Rf = 0.95 (pentane–Et2O, 9:1).
1H NMR (500 MHz, CDCl3): d = 7.42 (d, J = 8.2 Hz, 4 H, Ar), 7.13
(d, J = 8.2 Hz, 4 H, Ar), 2.62 (t, J = 7.7 Hz, 4 H, CH2), 1.99–2.10
(m, 4 H, CH2), 1.57–1.67 (m, 8 H, CH2), 1.36–1.40 (m, 8 H, CH2).
13C NMR (125.77 MHz, CDCl3): d = 142.76, 131.57, 128.40,
120.92, 109.13–121.02 (m, Rf8), 89.00, 35.75, 31.00 (t, J = 22.5
Hz), 30.88, 28.99, 28.78, 20.13 (t, J = 3.3 Hz). 
MS (MALDI-ICR, DCTB): m/z (%) = 1433.35 (45) [M + DCTB]+,
1182.20 (100) [M+].
1-(9,9,10,10,11,11,12,12,12-Nonafluorododecyl)-4-{[4-
(9,9,10,10,11,11,12,12,12-nonafluorododecyl)phenyl]eth-
ynyl}benzene (14g)
As described for 14a using bromoaryl 5g (11.4 g, 23.4 mmol),
Pd(PPh3)4 (1.62 g, 1.4 mmol), CuI (446 mg, 2.3 mmol), DBU (20.9
mL, 0.14 mol), THF (120 mL), H2O (150 mL, 9.4 mmol), and tri-
methylsilylacetylene (1.29 mL, 13.0 mmol) gave 14g (4.8 g, 50%);
Rf = 0.52 (pentane).
1H NMR (360 MHz, CDCl3): d = 7.43 (d, J = 8.2 Hz, 4 H, Ar), 7.15
(d, J = 8.2 Hz, 4 H, Ar), 2.61 (t, J = 7.3 Hz, 4 H, CH2), 1.97–2.12
(m, 4 H, CH2), 1.55–1.63 (m, 8 H, CH2), 1.28–1.39 (m, 16 H, CH2). 
13C NMR (90.55 MHz, CDCl3): d = 143.06, 131.48, 128.44, 120.65,
105.25–119.03 (m, Rf4), 88.92, 35.85, 31.19, 30.77 (t, J = 22.5 Hz),
29.06, 29.11, 29.13, 29.22, 20.06 (t, J = 3.3 Hz). 
MS (MALDI-ICR, DCTB): m/z (%) = 1089.44 (100) [M + DCTB]+,
838.29 (63) [M+].
1-(9,9,10,10,11,11,12,12,13,13,14,14,14-Tridecafluorotetra-
decyl)-4-{[4-(9,9,10,10,11,11,12,12,13,13,14,14,14-trideca-
fluorotetradecyl)phenyl]ethynyl}benzene (14h)
As described for 14a using iodoaryl 5h (2.0 g, 3.15 mmol),
Pd(PPh3)4 (219 mg, 0.19 mmol), CuI (60 mg, 0.32 mmol), DBU (2.8
mL, 18.9 mmol), THF (20 mL), H2O (23 mL, 1.26 mmol), and tri-
methylsilylacetylene (0.23 mL, 1.57 mmol) gave 14h (346 mg,
21%); Rf = 0.95 (pentane–Et2O, 9:1).
1H NMR (360 MHz, CDCl3): d = 7.43 (d, J = 8.2 Hz, 4 H, Ar), 7.15
(d, J = 8.2 Hz, 4 H, Ar), 2.61 (t, J = 7.7 Hz, 4 H, CH2), 1.97–2.12
(m, 4 H, CH2), 1.55–1.61 (m, 8 H, CH2), 1.28–1.39 (m, 16 H, CH2). 
13C NMR (90.55 MHz, CDCl3): d = 143.45, 131.87, 128.83, 121.05,
104.64–122.38 (m, Rf6), 89.31, 36.25, 31.57, 31.26 (t, J = 22.5 Hz),
29.46, 29.48, 29.51, 29.54, 20.47 (t, J = 3.3 Hz). 
MS (MALDI-ICR, DCTB): m/z (%) = 1289.43 (100) [M + DCTB]+,
1038.27 (91) [M+]. 
1-(9,9,10,10,11,11,12,12,13,13,14,14,15,15,16,16,16-Heptadeca-
fluorohexadecyl)-4-{[4-
(9,9,10,10,11,11,12,12,13,13,14,14,15,15,16,16,16-heptadeca-
fluorohexadecyl)phenyl]ethynyl}benzene (14i)
As described for 14a using iodoaryl 5i (3.8 g, 5.2 mmol), Pd(PPh3)4
(360 mg, 0.31 mmol), CuI (98.5 mg, 0.52 mmol), DBU (4.6 mL,
31.05 mmol), THF (30 mL), H2O (30 mL, 2.07 mmol), and trimeth-
ylsilylacetylene (0.38 mL, 2.6 mmol) gave 14i (680 mg, 21%);
Rf = 0.95 (pentane–Et2O, 9:1).
1H NMR (360 MHz, CDCl3): d = 7.43 (d, J = 8.2 Hz, 4 H, Ar), 7.15
(d, J = 8.2 Hz, 4 H, Ar), 2.61 (t, J = 7.7 Hz, 4 H, CH2), 1.99–2.14
(m, 4 H, CH2), 1.56–1.61 (m, 8 H, CH2), 1.28–1.39 (m, 16 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 143.05, 131.46, 128.43,
120.64, 105.02–118.85 (m, Rf8), 89.90, 35.84, 31.17, 30.86 (t,
J = 22.5 Hz), 29.03, 29.05, 29.06, 29.08, 20.07 (t, J = 3.3 Hz). 
MS (MALDI-ICR, DCTB): m/z (%) = 1489.41 (22) [M + DCTB]+,
1238.26 (100) [M]+.
1-(6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,13-Heptadecafluoro-
tridecyl)-4-{[4-(6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,13-hepta-
decafluorotridecyl)phenyl]ethynyl}benzene (14j)
An oven dried Schlenk reaction vessel was charged with freshly ac-
tivated Mg turning (87.5 mg, 3.6 mmol) under an inert atmosphere.
The Mg was stirred under vacuum for 1 h and heated with a heat
gun (3 ×). As soon as the reaction vessel reached r.t. THF (2 mL)
was syringed in under argon. 13-Bromo-
1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8-heptadecafluorotridecane (1.71 g,
3.0 mmol), dissolved in THF (2 mL) was syringed into the Mg sus-
pension. The sealed Schlenk tube was heated to 75 °C for 12 h. In a
second oven-dried Schlenk tube PdCl2(dppf)·CH2Cl2 (61.5 mg, 75
mmol) and 1-bromo-4-[(4-bromophenyl)ethynyl]benzene (252 mg,
0.74 mmol) were suspended under an inert atmosphere in THF (6
mL). The previously freshly prepared brownish Grignard soln was
diluted with THF (3 mL) and added by syringe. The Schlenk tube
was sealed and heated to 75 °C for 7 d and then the mixture was
quenched by the addition of MeOH (20 mL). The formed precipitate
was Büchner filtered and washed with MeOH and pentane. The ob-
tained solid was dissolved in CH2Cl2 (50 mL) and was washed with
H2O (3 × 50 mL). Removal of all volatiles of the organic fraction
and precipitation (Et2O–pentane) gave 14j (720 mg, 83%);
Rf = 0.77 (CH2Cl2–cyclohexane, 3:7).
1H NMR (360 MHz, CDCl3): d = 7.45 (d, J = 8.2 Hz, 4 H, Ar), 7.15
(d, J = 8.2 Hz, 4 H, Ar), 2.64 (t, J = 7.7 Hz, 4 H, CH2), 1.97–2.13
(m, 4  H, CH2), 1.61–1.71 (m, 8 H, CH2), 1.37–1.46 (m, 4 H, CH2).
13C NMR (125.77 MHz, CDCl3): d = 142.44, 131.54, 128.40,
120.80, 107.21–121.24 (m, Rf8), 88.91, 35.53, 30.78 (t, J = 22.1
Hz), 30.78, 28.58, 19.99.
MS (EI, 70 eV): m/z (%) = 1154.14 (10) [M+], 679.08 (100), 204.07
(70).
Hexakis[4-(4,4,5,5,6,6,7,7,8,8,9,9,9-tridecafluorononyl)phe-
nyl]benzene (15a); Typical Procedure
A two necked round bottomed flask was charged with tolane 14a
(2.8 g, 3.1 mmol) under an inert atmosphere. Addition of deoxygen-
ated dioxane (180 mL) followed by Co2(CO)8 (64 mg, 0.19 mmol)
under a positive pressure of argon, afforded a dark brown soln
which was refluxed for 60 h. Removal of the solvent under reduced
pressure yielded the crude target compound as a grey solid, which
was dissolved in pentane and agitated in an ultrasonic bath for 2 h.
Collection of the solid by suction filtration over Millipore® afforded
15a (2.4 g, 86%); Rf = 0.95 (pentane–Et2O, 9:1).
1H NMR (360 MHz, CDCl3): d = 6.70 (d, J = 7.7 Hz, 12 H, Ar), 6.63
(d, J = 7.7 Hz, 12 H, Ar), 2.43 (t, J = 6.8 Hz, 12 H, CH2), 1.71–1.83
(m, 24 H, CH2).
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13C NMR (90.55 MHz, CDCl3): d = 140.10, 138.75, 137.11, 131.65,
126.53, 104.19–120.29 (m, Rf6), 34.13, 29.71 (t, J = 22.5 Hz),
21.45.
MS (MALDI-ICR, DCTB): m/z (%) = 2695.34 (100) [M+].
Hexakis[4-(4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,11-heptadecafluo-
roundecyl)phenyl]benzene (15b) 
As described for 15a using tolane 14b (0.5 g, 0.45 mmol), Co2(CO)8
(12.4 mg, 36.4 mmol), dioxane (50 mL), and HFB (10mL) gave 15b
(0.42 g, 84%); Rf = 0.43 (pentane–Et2O, 1:1).
1H NMR (500 MHz, CDCl3): d = 6.74 (d, J = 8.2 Hz, 12 H, Ar), 6.66
(d, J = 8.2 Hz, 12 H, Ar), 2.45 (t, J = 7.3 Hz, 12 H, CH2), 1.81–1.91
(m, 12 H, CH2), 1.70–1.77 (m, 12 H, CH2).
13C NMR (125.77 MHz, CDCl3): d = 140.30, 138.99, 137.32,
131.83, 126.65, 105.32–120.11 (m, Rf8), 34.32, 30.14 (t, J = 22.1
Hz), 21.63.
MS (MALDI-ICR, DCTB): m/z (%) = 3294.22 (100) [M+], 2858.20
(10).
Hexakis[4-(5,5,6,6,7,7,8,8,8-nonafluorooctyl)phenyl]benzene 
(15c)
As described for 15a using tolane 14c (1.8 g, 2.48 mmol), Co2(CO)8
(51.0 mg, 0.15 mmol), and dioxane (150 mL) gave 15c (1.7 g, 95%);
Rf = 0.92 (pentane–Et2O, 9:1).
1H NMR (360 MHz, CDCl3): d = 6.68 (d, J = 8.2 Hz, 12 H, Ar), 6.62
(d, J = 8.2 Hz, 12 H, Ar), 2.39 (t, J = 6.8 Hz, 12 H, CH2), 1.90–2.03
(m, 12 H, CH2), 1.35–1.55 (m, 24 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 140.19, 138.52, 137.85, 131.58,
126.44, 105.63–121.06 (m, Rf4), 34.61, 30.45 (t, J = 22.5 Hz),
30.35, 18.94.
MS (MALDI-ICR, DCTB): m/z (%) = 2179.48 (100) [M+].
Hexakis[4-(5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,14-
henicosafluorotetradecyl)phenyl]benzene (15d)
As described for 15a using tolane 14d (0.2 g, 0.15 mmol), Co2(CO)8
(4.1 mg, 12.0 mmol), dioxane (10 mL), and HFB (10mL) gave 15d
(164 mg, 85%); Rf = 0.85 (BTF).
1H NMR (500 MHz, CDCl3): d = 6.66 (br d, J = 8.2 Hz, 12 H, Ar),
6.60 (br d, J = 8.2 Hz, 12 H, Ar), 2.33 (t, J = 6.8 Hz, 12 H, CH2),
1.97–2.08 (m, 12 H, CH2), 1.54–1.60 (m, 12 H, CH2), 1.36–1.42 (m,
12 H, CH2).
13C NMR (125.77 MHz, CDCl3): d = 140.33, 138.89, 138.44,
131.48, 126.43, 108.68–120.94 (m, Rf10), 35.32, 31.12, 30.83 (t,
J = 22.0 Hz), 20.17.
MS (MALDI-ICR, DCTB): m/z (%) = 3978.41 (100) [M+].
Hexakis[4-(6,6,7,7,8,8,9,9,10,10,11,11,11-tridecafluoro-
undecyl)phenyl]benzene (15e)
As described for 15a using tolane 14e (0.3 g, 0.31 mmol), Co2(CO)8
(8.6 mg, 25.0 mmol), and dioxane (20 mL) gave 15e (238 mg, 79%);
Rf = 0.95 (pentane–Et2O, 9:1).
1H NMR (360 MHz, CDCl3): d = 6.68 (d, J = 8.2 Hz, 12 H, Ar), 6.61
(d, J = 8.2 Hz, 12 H, Ar), 2.36 (t, J = 7.3 Hz, 12 H, CH2), 1.90–2.04
(m, 12 H, CH2), 1.47–1.55 (m, 12 H, CH2), 1.41–1.45 (m, 12 H,
CH2), 1.17–1.21 (m, 12 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 140.20, 138.43, 138.39, 131.45,
126.42, 110.39–118.72 (m, Rf6), 34.94, 30.79, 30.79 (t, J = 22.5
Hz), 28.07, 19.87 (t, J = 3.3 Hz). 
MS (MALDI-ICR, DCTB): m/z (%) = 2862.51 (100) [M+].
Hexakis[4-(7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,14-hepta-
decafluorotetradecyl)phenyl]benzene (15f)
As described for 15a using tolane 14f (1.0 g, 0.85 mmol), Co2(CO)8
(17.4 mg, 51.0 mmol), and dioxane (75 mL) gave 15f (0.64 g, 64%);
Rf = 0.98 (pentane–Et2O, 9:1).
1H NMR (500 MHz, CDCl3): d = 6.67 (d, J = 8.2 Hz, 12 H, Ar), 6.60
(d, J = 8.2 Hz, 12 H, Ar), 2.34 (t, J = 7.3 Hz, 12 H, CH2), 1.95–2.06
(m, 12 H, CH2), 1.49–1.56 (m, 12 H, CH2), 1.38–1.45 (m, 12 H,
CH2), 1.27–1.33 (m, 12 H, CH2), 1.11–1.17 (m, 12 H, CH2).
13C NMR (125.77 MHz, CDCl3): d = 140.31, 138.67, 138.48,
131.50, 126.43, 108.71–120.53 (m, Rf8), 35.12, 30.98 (t, J = 22.5
Hz), 30.85, 29.01, 28.34, 20.14 (t, J = 3.3 Hz). 
MS (MALDI-ICR, DCTB): m/z (%) = 3546.64 (100) [M+].
Hexakis[4-(9,9,10,10,11,11,12,12,12-nonafluorododecyl)phe-
nyl]benzene (15g)
As described for 15a using tolane 14g (2.5 g, 2.98 mmol), Co2(CO)8
(61 mg, 0.18 mmol), and dioxane (120 mL) gave 15g (1.82 g, 73%);
Rf = 0.97 (pentane–Et2O, 9:1).
1H NMR (360 MHz, CDCl3): d = 6.67 (d, J = 8.2 Hz, 12 H, Ar), 6.61
(d, J = 8.2 Hz, 12 H, Ar), 2.34 (t, J = 7.3 Hz, 12 H, CH2), 1.95–2.10
(m, 12 H, CH2), 1.50–1.61 (m, 24 H, CH2), 1.25–1.39 (m, 48 H,
CH2). 
13C NMR (90.55 MHz, CDCl3): d = 140.27, 138.85, 138.33, 131.42,
126.43, 107.63–122.18 (m, Rf4), 35.29, 31.13, 30.77 (t, J = 22.5 Hz,
CH2), 28.70. 28.93, 29.13, 29.24, 20.07 (t, J = 3.3 Hz). 
MS (MALDI-ICR, DCTB): m/z (%) = 2514.85 (100) [M+].
Hexakis[4-(9,9,10,10,11,11,12,12,13,13,14,14,14-tridecafluoro-
tetradecyl)phenyl]benzene (15h)
As described for 15a using tolane 14h (0.3 g, 0.29 mmol), Co2(CO)8
(5.9 mg, 17.0 mmol), and dioxane (25 mL) gave 15h (275 mg, 92%);
Rf = 0.95 (pentane–Et2O, 9:1).
1H NMR (360 MHz, CDCl3): d = 6.67 (d, J = 8.2 Hz, 12 H, Ar), 6.61
(d, J = 8.2 Hz, 12 H, Ar), 2.34 (t, J = 7.3 Hz, 12 H, CH2), 1.95–2.10
(m, 12 H, CH2), 1.50–1.61 (m, 24 H, CH2), 1.21–1.41 (m, 48 H,
CH2). 
13C NMR (90.55 MHz, CDCl3): d = 140.27, 138.86, 138.33, 131.42,
126.44, 105.03–119.65 (m, Rf6), 35.31, 31.15, 30.77 (t, J = 22.5
Hz), 28.70, 28.95, 29.15, 29.27, 20.10 (t, J = 3.3 Hz). 
MS (MALDI-ICR, DCTB): m/z (%) = 3114.82 (100) [M+].
Hexakis[4-(9,9,10,10,11,11,12,12,13,13,14,14,15,15,16,16,16-
heptadecafluorohexadecyl)phenyl]benzene (15i)
As described for 15a using tolane 14i (659 mg, 0.53 mmol),
Co2(CO)8 (10.8 mg, 31.6 mmol), and dioxane (50 mL) gave 15i (329
mg, 51%); Rf = 0.95 (pentane–Et2O, 9:1).
1H NMR (500 MHz, CDCl3): d = 6.66 (d, J = 8.2 Hz, 12 H, Ar), 6.60
(d, J = 8.2 Hz, 12 H, Ar), 2.33 (t, J = 7.3 Hz, 12 H, CH2), 1.97–2.08
(m, 12 H, CH2), 1.54–1.60 (m, 12 H, CH2), 1.35–1.42 (m, 12 H,
CH2), 1.30–1.35 (m, 12 H, CH2), 1.09–1.28 (m, 36 H, CH2).
13C NMR (125.77 MHz, CDCl3): d = 140.33, 138.89, 138.44,
131.48, 126.43, 108.68–120.94 (m, Rf8), 35.32, 31.12, 31.01 (t,
J = 22.5 Hz), 28.72, 28.96, 29.17, 29.24, 20.17 (t, J = 3.3 Hz). 
MS (MALDI-ICR, DCTB): m/z (%) = 3714.72 (100) [M+].
Hexakis[4-(6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,13-hepta-
decafluorotridecyl)phenyl]benzene (15j)
As described for 15a using tolane 14j (231 mg, 0.20 mmol),
Co2(CO)8 (10.7 mg, 31.2 mmol), and dioxane (75 mL) gave 15j (191
g, 83%); Rf = 0.95 (pentane–Et2O, 5:1).
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1H NMR (360 MHz, CDCl3): d = 6.69 (d, J = 8.2 Hz, 12 H, Ar), 6.61
(d, J = 8.2 Hz, 12 H, Ar), 2.36 (t, J = 7.3 Hz, 12 H, CH2), 1.88–2.04
(m, 12 H, CH2), 1.47–1.55 (m, 12 H, CH2), 1.36–1.45 (m, 12 H,
CH2), 1.14–1.21 (m, 12 H, CH2).
13C NMR (125.77 MHz, CDCl3): d = 140.29, 138.55, 138.45,
131.54, 126.43, 108.67–120.49 (m, Rf8), 34.97, 30.92 (t, J = 22.1
Hz), 30.78, 28.13, 19.96.
MS (MALDI-ICR, DCTB): m/z (%) = 3462.41 (100) [M+], 2973.41
(10).
1,1,1,2,2,3,3,4,4,5,5,6,6,12,12,13,13,14,14,15,15,16,16,17,17,17-
Hexacosafluoroheptadecan-9-ol (18)
To a stirred soln of the Grignard reagent prepared from
1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluoro-8-iodooctane (50 g, 102
mmol) and Mg (3.7 g, 152 mmol) in anhyd Et2O (150 mL) under ar-
gon at 25 °C was added dropwise a soln of ethyl formate (3.1 g, 42
mmol) in anhyd Et2O (6 mL). The mixture was stirred at r.t. over-
night. It was then quenched by a slow addition of H2O (100 mL), ex-
tracted with Et2O (3 × 50 mL), washed with sat. NaCl (50 mL),
dried (Na2SO4), and evaporated. The product was purified by filtra-
tion (silica gel, pentane). Elution with Et2O and evaporation of the
solvent afforded the title compound (30.6 g, 81%); Rf = 0.65 (pen-
tane).
1H NMR (360 MHz, CDCl3): d = 3.75 (m, 1 H, CH), 2.04–2.45 (m,
4 H, CH2), 1.68–1.90 (m, 4 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 108–122 (m, Rf6), 69.62, 28.02,
27.22 (t, J = 22 Hz).
MS (EI, 70 eV): m/z (%) = 707.7 (1), 377.3 (100), 357.3 (82).
1,1,1,2,2,3,3,4,4,8,8,9,9,10,10,11,11,11-Octadecafluoro-6-iodo-
undecane (19a)
As described for 8a using 4,4,5,5,6,6,7,7,7-nonafluorohept-1-ene
(20, 5.5 g, 21.14 mmol), perfluorobutyl iodide (7.67 g, 22.18
mmol), AIBN (170 mg, 1.05 mmol), and 30% aq Na2S2O5 soln (3.5
mL) gave 19a (6.36 mg, 49%); Rf = 0.95 (pentane).
1H NMR (360 MHz, CDCl3): d = 4.52 (quint, J = 6.8 Hz, 1 H, CH),
2.89–3.02 (m, 4 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 106.21–119.36 (m, Rf4), 41.97
(t, J = 21.1 Hz), 0.00. 
MS (EI, 70 eV): m/z (%) = 606.4 (5) [M+], 479.4 (30), 459.4 (41),
245.2 (69), 195.1 (95), 69.0 (100).
1,1,1,2,2,3,3,4,4,5,5,6,6,12,12,13,13,14,14,15,15,16,16,17,17,17-
Hexacosafluoro-9-iodoheptadecane (19b)
To a flask containing a stirring mixture of DDQ (3.76 g, 16.6
mmol), Ph3P (4.35 g, 16.6 mmol), and TBAI (6.1 g, 16.6 mmol) in
CH2Cl2 (140 mL), 18 (10.0 g, 13.8 mmol) was added at r.t. and the
mixture was stirred for 2 h. The yellow color of the mixture changed
to red. The concentrated residue was filtered (silica gel, pentane)
and evaporated to afford 19b (10.6 g, 90%); Rf = 0.92 (pentane).
1H NMR (360 MHz, CDCl3): d = 4.04 (m, 1 H, CH), 2.06–2.6 (m,
4 H, CH2), 2.06–2.3 (m, 4 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 108–122 (m, Rf6), 32.61, 31.58,
31.58 (t, J = 22 Hz).
MS (EI, 70 eV): m/z (%) = 707.7 (46), 687.7 (20), 437.4 (24), 327.3
(100).
6,6,7,7,8,8,9,9,9-Nonafluoro-4-(2,2,3,3,4,4,5,5,5-nonafluoropen-
tyl)non-1-ene (21a); Typical Procedure
An oven-dried Schlenk tube was charged with Pd(dppf)Cl2·CH2Cl2
(250 mg, 0.30 mmol) under an inert atmosphere. Compound 19a
(6.3 g, 10.4 mmol) was separately deoxygenated, diluted with THF
(16 mL), and added by syringe to the Schlenk tube. The mixture was
then cooled to 0 °C in an ice/NaCl bath. Allylmagnesium bromide
(1 M in Et2O; 14.6 mL, 14.6 mmol) was added slowly by syringe (2
h), yielding a yellow soln. The ice bath was removed after the addi-
tion was completed and the mixture (green) was stirred at r.t. for 16
h and quenched with MeOH (8 mL). All volatiles were removed un-
der reduced pressure yielding a brown suspension that was filtered
through a silica gel plug (pentane) under reduced pressure to give
21a (3.86 g, 71%); Rf = 0.95 (pentane).
1H NMR (360 MHz, CDCl3): d = 5.72 (ddt, J = 17.0, 10.0, 6.8 Hz,
1 H, CH), 5.19 (d, J = 17.0 Hz, 1 H, CH2), 5.14 (d, J = 10.0 Hz, 1
H, CH2), 2.54 (sept, J = 6.8 Hz, 1 H, CH), 2.33 (t, J = 6.8 Hz, 2 H,
CH2), 2.12–2.27 (m, 4 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 133.5, 119.40, 108.86–118.89
(m, Rf4), 38.78, 33.53 (t, J = 21.1 Hz), 24.91. 
MS (EI, 70 eV): m/z (%) = 520.5 (7) [M+], 287.3 (100).
7,7,8,8,9,9,10,10,11,11,12,12,12-Tridecafluoro-4-
(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)dodec-1-ene (21b)
As described for 21a using allyl 19b (9.5 g, 11.4 mmol),
Pd(dppf)Cl2·CH2Cl2 (372 mg, 0.5 mmol), allylmagnesium bromide
(1 M in Et2O; 17.1 mL, 17.1 mmol), and THF (30 mL) gave 21b
(7.1 g, 84%); Rf = 0.93 (pentane).
1H NMR (360 MHz, CDCl3): d = 5.73 (ddt, J = 16.8, 10.0, 6.8 Hz,
1 H, CH), 5.11 (dd, J = 10.0, 1.4 Hz, 1 H, CH), 5.09 (dd, J = 16.8,
1.4 Hz, 1 H, CH), 2.10 (m, 6 H, CH2), 1.61 (m, 5 H, CH2, CH).
13C NMR (90.55 MHz, CDCl3): d = 134.94, 108–122 (m, Rf6),
117.79, 37.23, 36.29, 28.27 (t, J = 22 Hz), 23.33.
MS (EI, 70 eV): m/z (%) = 748.7 (2) [M+], 720.7 (6), 706.6 (12),
401.4 (72), 387.3 (100).
1-Bromo-4-[6,6,7,7,8,8,9,9,9-nonafluoro-4-(2,2,3,3,4,4,5,5,5-
nonafluoropentyl)non-1-enyl]benzene (22a); Typical Procedure
As described for 4a using 21a (0.52 g, 1.0 mmol), 4-bromobenzene-
diazonium tetrafluoroborate (0.3 g, 1.1 mmol), Pd2(dba)3 (15.5 mg,
15 mmol), NaOAc (287 mg, 3.5 mmol), and MeCN (5 mL) gave 22a
(200 mg, 31%); Rf = 0.71 (pentane).
1H NMR (360 MHz, CDCl3): d = 7.44 (d, J = 8.2 Hz, 2 H, Ar), 7.22
(d, J = 8.2 Hz, 2 H, Ar), 6.42 (d, J = 15.8 Hz, 1 H, CH), 6.06 (dt,
J = 15.8, 7.3 Hz, 1 H, CH), 2.63 (sept, J = 6.4 Hz, 1 H, CH), 2.48 (t,
J = 7.3 Hz, 2 H, CH2), 2.18–2.30 (m, 4 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 135.63, 133.31, 131.75, 127.70,
125.65, 121.45, 109.82–120.05 (m, Rf4), 37.95, 33.69 (t, J = 21.1
Hz), 25.46.
MS (EI, 70 eV): m/z (%) = 674.6 (2) [M+], 197.1 (30), 116.0 (100).
1-Bromo-4-[7,7,8,8,9,9,10,10,11,11,12,12,12-tridecafluoro-4-
(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)dodec-1-enyl]ben-
zene (22b)
As described for 22a using 21b (5.0  g, 6.7 mmol), 4-bromoben-
zenediazonium tetrafluoroborate (2.0 g, 7.4 mmol), Pd2(dba)3 (104
mg, 0.1 mmol), NaOAc (1.92 g, 23.5 mmol), and MeCN (40 mL)
gave 22b (3.8 g, 63%); Rf = 0.78 (pentane).
1H NMR (500 MHz, CDCl3): d = 7.43 (d, J = 8.5 Hz, 2 H, Ar), 7.20
(d, J = 8.5 Hz, 2 H, Ar), 6.38 (d, J = 15.8 Hz, 1 H, CH), 6.11 (dt,
J = 15.8, 7.4 Hz, 1 H, CH), 2.25 (m, 2 H, CH2), 2.10 (m, 4 H, CH2),
1.66 (m, 5 H, CH2, CH).
13C NMR (125 MHz, CDCl3): d = 136.00, 131.76, 131.69, 127.58,
127.30, 121.26, 108–122 (m, Rf6), 36.65, 36.37, 28.16 (t, J = 20.8
Hz), 23.35.
MS (EI, 70 eV): m/z (%) = 903.7 (74) [M+], 805.0 (30), 475.5 (100). 
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1-Bromo-4-[6,6,7,7,8,8,9,9,9-nonafluoro-4-(2,2,3,3,4,4,5,5,6,6,6-
nonafluoropentyl)nonyl]benzene (23a)
As described for 5a using alkene 22a (1.75 g, 2.6 mmol), Rh/C (100
mg), pentane (20 mL), and CH2Cl2 (10 mL) gave 23a (1.75 g, 98%);
Rf = 0.81 (pentane).
1H NMR (500 MHz, CDCl3): d = 7.41 (d, J = 8.2 Hz, 2 H, Ar), 7.04
(d, J = 8.2 Hz, 2 H, Ar), 2.59 (t, J = 7.0 Hz, 2 H, CH2), 2.44 (sept,
J = 5.9 Hz, 1 H, CH), 2.09–2.24 (m, 4 H, CH2), 1.58–1.66 (m, 4 H,
CH2).
13C NMR (125 MHz, CDCl3): d = 140.48, 131.50, 130.05, 119.78,
108.52–121.21 (m, Rf4), 35.01, 34.24, 34.13 (t, J = 21.1 Hz), 27.76,
25.34.
MS (EI, 70 eV): m/z (%) = 676.6 (6) [M+], 171.0 (100).
1-Bromo-4-[7,7,8,8,9,9,10,10,11,11,12,12,12-tridecafluoro-4-
(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)dodecyl]benzene 
(23b)
As described for 5a using alkene 22b (2.26 g, 2.5 mmol), Rh/C (250
mg), pentane (25 mL), and CH2Cl2 (25 mL) gave 23b (1.75 g, 77%);
Rf = 0.87 (pentane).
1H NMR (360 MHz, CDCl3): d = 7.41 (d, J = 8.5 Hz, 2 H, Ar), 7.05
(d, J = 8.5 Hz, 2 H, Ar), 2.58 (t, J = 7.5 Hz, 2 H, CH2), 2.01 (m, 4
H, CH2), 1.60 (m, 7 H, CH2, CH), 1.32 (m, 2 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 140.95, 131.62, 130.21, 119.84,
108–122, 36.29, 35.45, 32.08, 28.12 (t, J = 21.1 Hz), 27.90, 23.24.
MS (EI, 70 eV): m/z (%) = 906.0 (100) [M+], 826 (4), 373.3 (32).
1-Bromo-4-[9,9,10,10,11,11,12,12,13,13,14,14,14-tridecafluoro-
6-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)tetradecyl]ben-
zene (23c)
As described for 5a using alkyne 27 (463 mg, 0.5 mmol), Rh/C (42
mg), pentane (5 mL), and CH2Cl2 (5 mL) gave 23c (400 mg, 86%);
Rf = 0.79 (pentane).
1H NMR (360 MHz, CDCl3): d = 7.39 (d, J = 8.6 Hz, 2 H, Ar), 7.04
(d, J = 8.6 Hz, 2 H, Ar), 2.56 (t, J = 7.3 Hz, 2 H, CH2), 2.04 (m, 4
H, CH2), 1.53–1.66 (m, 7 H, CH2, CH), 1.30 (m, 6 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 141.61, 131.84, 130.29, 118.96,
108–122, 36.44, 35.41, 32.76, 31.34, 29.47, 28.18 (t, J = 21.1 Hz),
26.27, 23.30.
MS (EI, 70 eV): m/z (%) = 854.7 (12), 687.4 (10), 327.4 (100).
7,7,8,8,9,9,10,10,11,11,12,12,12-Tridecafluoro-4-
(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)dodecan-1-ol (24)
To a 2-necked flask under argon with a stirred suspension of AlCl3
(4.17 g, 31.2 mmol) in Et2O (12 mL) was added LiAlH4 (0.4 g, 10.4
mmol) at 0 °C. After 15 min, PhB(OH)2 (63 mg, 0.52 mmol), and
21b (7.8 g, 10.4 mmol) were added. The resulting mixture was al-
lowed to warm to r.t. and stirred at this temperature and then the in-
ert gas protection was removed. Stirring was continued overnight
under air. The mixture was quenched with 1 M HCl (10 mL), ex-
tracted with Et2O (3 × 25 mL), dried (Na2SO4), and concentrated.
The product was purified by filtration (silica gel, pentane then
Et2O). Evaporation afforded 24 (3.73 g, 47%); Rf = 0.72 (pentane).
1H NMR (360 MHz, CDCl3): d = 3.67 (t, J = 6.1 Hz, 2 H, CH2), 2.06
(m, 6 H, CH2), 1.3–1.7 (m, 7 H, CH2, CH).
13C NMR (90.55 MHz, CDCl3): d = 108–122 (m, Rf6), 69.89, 36.30,
29.39, 28.91, 28.15 (t, J = 22 Hz), 23.33.
MS (EI, 70 eV): m/z (%) = 720.9 (10), 401.4 (100), 357.3 (82).
9-(3-Bromopropyl)-
1,1,1,2,2,3,3,4,4,5,5,6,6,12,12,13,13,14,14,15,15,16,16,17,17,17-
hexacosafluoroheptadecane (25)
As described for 19b using alcohol 24 (3.43 g, 4.48 mmol), DDQ
(1.22 g, 5.38 mmol), Ph3P (1.41 g, 5.38 mmol), TBAB (1.74 g, 5.38
mmol), and CH2Cl2 (50 mL) gave 25 (3.13 g, 84%); Rf = 0.87 (pen-
tane).
1H NMR (360 MHz, CDCl3): d = 3.42 (m, 2 H, CH2), 2.08 (m, 4 H,
CH2), 1.87 (m, 2 H, CH2), 1.4–1.8 (m, 7 H, CH2, CH).
13C NMR (90.55 MHz, CDCl3): d = 108–122 (m, Rf6), 35.88, 33.57,
31.16, 29.38, 28.12 (t, J = 22 Hz), 23.30.
MS (EI, 70 eV): m/z (%) = 749.9 (2), 481.4 (12), 401.5 (100).
9,9,10,10,11,11,12,12,13,13,14,14,14-Tridecafluoro-6-
(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)tetradec-1-yne (26)
As described for 11a using bromide 25 (3.0 g, 3.62 mmol), lithium
acetylide–ethylenediamine complex (1.11 g, 10.85 mmol), DMSO
(10 mL), and pentane (4 mL) gave 26 (1.67 g, 60%); Rf = 0.84 (pen-
tane).
1H NMR (360 MHz, CDCl3): d = 2.22 (dt, J = 6.8, 2.3 Hz, 2 H,
CH2), 2.0–2.14 (m, 4 H, CH2), 1.96 (t, J = 2.3 Hz, 1 H, CH), 1.77
(dt, J = 6.3, 2.3 Hz, 2 H, CH2), 1.4–1.67 (m, 7 H, CH2, CH).
13C NMR (90.55 MHz, CDCl3): d = 108–122 (m, Rf6), 83.89, 68.97,
36.02, 31.51, 28.15 (t, J = 22 Hz), 24.99, 23.31, 18.61.
MS (EI, 70 eV): m/z (%) = 441.5 (8), 427.5 (100).
1-Bromo-4-[9,9,10,10,11,11,12,12,13,13,14,14,14-tridecafluoro-
6-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)tetradec-1-
ynyl]benzene (27)
As described for 12a using alkyne 26 (1.34 g, 1.74 mmol),
PdCl2(PPh3)2 (66 mg, 0.09 mmol), CuI (31 mg, 0.16 mmol), 1-bro-
mo-4-iodobenzene (442 mg, 1.56 mmol), Et3N (12.0 mL, 86.4
mmol), and BTF (12 mL) gave 27 (463 mg, 30%); Rf = 0.56 (pen-
tane).
1H NMR (360 MHz, CDCl3): d = 7.41 (d, J = 8.6 Hz, 2 H, Ar), 7.25
(d, J = 8.6 Hz, 2 H, Ar), 2.42 (t, J = 6.8 Hz, 2 H, CH2), 2.08 (m, 4
H, CH2), 1.48–1.64 (m, 9 H, CH2, CH).
13C NMR (90.55 MHz, CDCl3): d = 133.08, 131.61, 122.75, 121.98,
108–122 (m, Rf6), 90.71, 80.41, 36.09, 31.79, 28.18 (t, J = 20.8 Hz),
25.27, 23.33, 19.66.
MS (EI, 70 eV): m/z (%) = 760.0 (4), 581.6 (100), 516.6 (20). 
1-[6,6,7,7,8,8,9,9,9-Nonafluoro-4-(2,2,3,3,4,4,5,5,5-nonafluoro-
pentyl) nonyl]-4-({4-[6,6,7,7,8,8,9,9,9-nonafluoro-4-
(2,2,3,3,4,4,5,5,5-nonafluoropentyl)nonyl]phenyl}ethynyl)ben-
zene (28a)
As described for 14a using bromoaryl 23a (1.0 g, 1.48 mmol),
Pd(PPh3)4 (103 mg, 89 mmol), CuI (28 mg, 0.15 mmol), DBU (1.32
mL, 8.9 mmol), THF (10 mL), H2O (10 mL, 0.59 mmol), and tri-
methylsilylacetylene (0.11 mL, 0.74 mmol) gave 28a (530 mg,
59%); Rf = 0.15 (pentane).
1H NMR (360 MHz, CDCl3): d = 7.45 (d, J = 8.2 Hz, 4 H, Ar), 7.15
(d, J = 8.2 Hz, 4 H, Ar), 2.65 (t, J = 7.1 Hz, 4 H, CH2), 2.45 (sept,
J = 6.0 Hz, 2 H, CH), 2.05–2.26 (m, 8 H, CH2), 1.61–1.69 (m, 8 H,
CH2).
13C NMR (90.55 MHz, CDCl3): d = 141.83, 131.66, 128.34, 121.06,
108.10–120.69 (m, Rf6), 88.95, 35.52, 34.31, 34.16 (t, J = 21.1 Hz),
27.66, 25.37.
MS (MALDI-ICR, DCTB): m/z (%) = 1469.33 (99) [M + DCTB]+,
1218.18 (100) [M+].
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1-[7,7,8,8,9,9,10,10,11,11,12,12,12-Tridecafluoro-4-
(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)dodecyl]-4-({4-
[7,7,8,8,9,9,10,10,11,11,12,12,12-tridecafluoro-4-
(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)dodecyl]phe-
nyl}ethynyl)benzene (28b)
As described for 14a using bromoaryl 23b (0.5 g, 0.52 mmol),
Pd(PPh3)4 (36.4 mg, 30 mmol), CuI 9.9 mg, 50 mmol), DBU (0.48
mL, 3.12 mmol), THF (5 mL), H2O (3.7 mL, 0.21 mmol), and tri-
methylsilylacetylene (37.7 mL, 0.26 mmol) gave 28b (410 mg,
94%); Rf = 0.12 (pentane).
1H NMR (360 MHz, CDCl3): d = 7.44 (d, J = 8.5 Hz, 4 H, Ar), 7.14
(d, J = 8.5 Hz, 4 H, Ar), 2.63 (t, J = 7.5 Hz, 4 H, CH2), 2.01 (m, 8
H, CH2), 1.60 (m, 14 H, CH2, CH), 1.32 (m, 4 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 142.27, 131.76, 128.49,
108.13–122.98 (m, Rf6), 121.15, 89.03, 36.29, 35.94, 32.06, 28.13
(t, J = 22.1 Hz), 27.76, 23.27.
MS (MALDI-TOF, DCTB): m/z (%) = 1673.81 (100) [M+].
1-[9,9,10,10,11,11,12,12,13,13,14,14,14-Tridecafluoro-6-
(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)tetradecyl]-4-({4-
[9,9,10,10,11,11,12,12,13,13,14,14,14-tridecafluoro-6-
(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)tetradecyl]phe-
nyl}ethynyl)benzene (28c)
As described for 14a using bromoaryl 23c (289 mg, 0.31 mmol),
Pd(PPh3)4 (22 mg, 20 mmol), CuI 6.0 mg, 30 mmol), DBU (0.28 mL,
1.86 mmol), THF (5 mL), H2O (3.0 mL, 0.12 mmol), and trimethyl-
silylacetylene (21.7 mL, 0.15 mmol) gave 28c (203 mg, 76%);
Rf = 0.12 (pentane).
1H NMR (500 MHz, CDCl3): d = 7.43 (d, J = 8.2 Hz, 4 H, Ar), 7.14
(d, J = 8.2 Hz, 4 H, Ar), 2.62 (t, J = 7.6 Hz, 4 H, CH2), 2.04 (m, 8
H, CH2), 1.58 (m, 14 H, CH2, CH), 1.31 (m, 12 H, CH2).
13C NMR (125 MHz, CDCl3): d = 142.65, 131.65, 128.57, 120.90,
108.05–120.83 (m, Rf6), 89.06, 36.44, 35.93, 32.78, 31.23, 29.47,
28.22 (t, J = 21.1 Hz), 26.28, 23.35.
MS (MALDI-TOF, DCTB): m/z (%) = 1729.98 (100) [M+].
Hexakis{4-[6,6,7,7,8,8,9,9,9-nonafluoro-4-(2,2,3,3,4,4,5,5,5-
nonafluoropentyl)nonyl]phenyl}benzene (29a)
As described for 15a using tolane 28a (0.5 g, 0.41 mmol), Co2(CO)8
(11.2 mg, 33.0 mmol), and dioxane (50 mL) gave 29a (0.42 g, 84%);
Rf = 0.21 (pentane–Et2O, 99:1).
1H NMR (500 MHz, CDCl3): d = 6.70 (d, J = 8.2 Hz, 12 H, Ar), 6.61
(d, J = 8.2 Hz, 12 H, Ar), 2.34–2.36 (m, 18 H, CH and CH2), 2.01–
2.20 (m, 24 H, CH2), 1.35–1.45 (m, 24 H, CH2).
13C NMR (125 MHz, CDCl3): d = 140.18, 138.60, 137.81, 131.57,
126.33, 106.14–120.41 (m, Rf4), 34.74, 34.05 (t, J = 21.1 Hz),
33.81, 27.36, 25.15.
MS (MALDI-ICR, DCTB): m/z (%) = 3655.50 (100) [M+].
Hexakis{4-[7,7,8,8,9,9,10,10,11,11,12,12,12-tridecafluoro-4-
(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)dodecyl]phe-
nyl}benzene (29b)
As described for 15a using tolane 28b (345 mg, 0.21 mmol),
Co2(CO)8 (6 mg, 20.0 mmol), and dioxane (40 mL) gave 29b (159
mg, 46%).
1H NMR (500 MHz, CDCl3): d = 6.71 (d, J = 8.3 Hz, 12 H, Ar), 6.61
(d, J = 8.3 Hz, 12 H, Ar), 2.35 (t, J = 7.1 Hz, 12 H, CH2), 1.99 (m,
24 H, CH2), 1.52 (m, 24 H, CH2), 1.42 (m, 18 H, CH2, CH), 1.13 (m,
12 H, CH2).
13C NMR (125 MHz, CDCl3): d = 140.48, 138.92, 138.40, 131.80,
126.48, 108.56–122.29 (m, Rf6), 36.38, 35.38, 32.23, 28.38 (t,
J = 22 Hz), 27.83, 23.48.
MS (MALDI-TOF, DCTB): m/z (%) = 5023.98 (5) [M+], 975.25
(100).
Hexakis{4-[9,9,10,10,11,11,12,12,13,13,14,14,14-tridecafluoro-
6-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)tetradecyl]phe-
nyl}benzene (29c)
As described for 15a using tolane 28c (190 mg, 0.11 mmol),
Co2(CO)8 (10 mg, 30.0 mmol), and dioxane (25 mL) gave 29c (140
mg, 74%).
1H NMR (360 MHz, CDCl3): d = 6.66 (d, J = 8.2 Hz, 12 H, Ar), 6.59
(d, J = 8.2 Hz, 12 H, Ar), 2.34 (t, J = 7.3 Hz, 12 H, CH2), 2.02 (m,
24 H, CH2), 1.56 (m, 24 H, CH2), 1.42 (m, 18 H, CH2, CH), 1.10–
1.32 (m, 36 H, CH2).
13C NMR (90.55 MHz, CDCl3): d = 140.35, 138.73, 138.53, 131.58,
126.52, 108.34–22.67 (m, Rf6), 36.43, 35.33, 32.84, 31.16, 28.99,
28.08 (t, J = 21.1 Hz), 26.16, 23.22.
MS (MALDI-TOF, DCTB): m/z (%) = 5192.29 (100) [M+], 3492.82
(8), 1731.95 (17).
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